

**QUEEN'S UNIVERSITY
DEPARTMENT OF PATHOLOGY**



**FACULTY OF HEALTH SCIENCES
ANNUAL REPORT
2001**

DR. PAUL MANLEY, M.D. - CHAIRMAN

**DEPARTMENT OF PATHOLOGY
2001
ANNUAL REPORT**

TABLE OF CONTENTS

Introduction

Faculty, Administration and Laboratory Managers and Supervisors

Laboratory Medicine and Pathology

Clinical Laboratories of Eastern Ontario (CLEO)

Personnel, Awards and Significant Events

Undergraduate, Graduate and Postgraduate Educational Programs

Research Projects and Grants in Progress

Department of Pathology Visiting Lecturers

Senior Staff Department of Pathology and Queen's University Lectures

Senior Staff Department of Pathology - Invited Lectures Outside of Kingston

Senior Staff Committees

Editorial Boards and Grant Review Committees

Full Papers Published and in Press

Abstracts

(Report written April 2002)

**FACULTY, ADMINISTRATION
AND
LABORATORY MANAGERS AND SUPERVISORS**

**DEPARTMENT OF PATHOLOGY
FACULTY**

2001

PROFESSOR AND HEAD

Dr. Paul Manley

PROFESSORS

Dr. A.F. Clark*

Dr. S. Cole

Dr. R. Deeley

Dr. B. Elliott

Dr. R. Kisilevsky (On sabbatical Sep. 1, 2001-Aug. 30, 2002)

Dr. D. Lillicrap

Dr. S. Ludwin

Dr. P.G. Young*

ASSOCIATE PROFESSORS

Dr. S. Boag

Dr. C. Collier

Dr. D. Dexter

Dr. W.A. Fletcher

Dr. S. Ford

Dr. P. Greer

Dr. M. Khalifa*

Dr. D. LeBrun

Dr. D. Maurice** (On sabbatical July 1, 2000-June 30, 2001)

Dr. C. Mueller*

Dr. L. Mulligan*

Dr. M. Petkovich*

Dr. L. Raptis*

Dr. J. Rossiter

Dr. S. SenGupta

Dr. L. Shepherd

Dr. S. Taylor

Dr. L. Tomalty*

Dr. I. Young

Dr. D. Zoutman

ASSISTANT PROFESSORS

Dr. M. Arquint

Dr. S. Davey***

Dr. G. Evans*

Dr. K. Harrison

Dr. D. Hurlbut

Dr. T. Karnauchow

Dr. D. Lee*

ASSISTANT PROFESSORS

(cont'd)

Dr. D. Rapson (0.7 part-time)
Dr. M. Raymond
Dr. J. Rossiter
Dr. C. Rowlands

LECTURER

Dr. J. Raymond

**ADJUNCT ACADEMIC
GROUP I**

Dr. J. Ancsin
Dr. D. Connor
Dr. A. Duncan
Dr. H. Feilotter
Dr. D. Haust
Mr. L. Kennedy
Dr. A. Lagarde
Mr. D. Piper
Dr. D.M. Robertson, Emeritus
Dr. J. Samis
Dr. V. Walley

ADMINISTRATION

Laboratory Manager	- Mr. David Piper
Administrative Assistant	- Mrs. Marg McIlroy
Administrative Assistant	- Mrs. Barb Latimer

**LABORATORY MANAGERS
AND SUPERVISORS**

Anatomic Pathology	- Mr. Dave More
Chemistry	- Mrs. Mary Waugh
Cytogenetics	- Ms. Anne Hanley
Microbiology	- Ms. Linda Fidler
CLEO	- Mr. Dave More

***Cross-Appointed Staff**

**** Primary Switched to Pharmacology & Toxicology effective July 1, 2001**

*****Cross-Appointment until June 30, 2001, Adjunct I effective July 1, 2001**

**LABORATORY MEDICINE
AND
PATHOLOGY**

INTRODUCTION & EXECUTIVE SUMMARY

Pathology as a discipline bridges the interface between basic medical science and clinical practice.

Therefore the role of the Queen's Department of Pathology is distinctive at the Medical School; while playing a major role in the educational and research aspects of the school, it functions as both a basic science and a clinical department; and is also responsible for one of the most technically and administratively complex service departments in the affiliated hospitals.

The Department has achieved excellence in many areas of its mandate, by building on a policy of commitment to academic excellence, taking into consideration the unique features offered by the local Queen's and regional environments. Of great importance has been the establishment of a common set of values throughout the Department, in which mutual respect for excellence in all of the various aspects of Departmental work has been achieved among its members, and in which there has been little internal dissension about the need to mutually support the various diverse endeavours of the Department. In these endeavours, the strategic plan of the Department, and its vision are remarkably consonant with the recently articulated Faculty Vision Statement.

The educational aspects of the Department have traditionally been very strong. The Pathology Department is unique in that it offers a complete range of educational facilities, from Undergraduate Medical, Undergraduate Life Sciences and Graduate Studies, to Postgraduate Resident levels. The evolution of teaching to Undergraduate Medical students has progressed from the delivery of traditional courses in General and Special Pathology under the old curriculum, to the integrated teaching of the new curriculum, a process still in progress, but one which has been readily embraced by the Department, which has shown a willingness to take a leadership role in the process. The Undergraduate Life Science programme has progressively expanded at Queen's, and concurrent with this, the enrolment in courses given by the Pathology Department has steadily increased. The Pathology Department is actively pursuing, together with other Basic Science departments, methods of collaborative teaching in this important programme. The Department's Graduate Studies programme has increased dramatically since its inception, with a major increase in a number of Graduate students, including progressively more PhD students, studying and doing research within the Department.

Traditionally, residency training in the Department has been very strong, with 4 programmes recently re-accredited by the Royal College of Physicians of Canada, being offered. Queen's graduates have had a remarkably high rate of success in examinations in these programmes, and have gone on to take jobs in both the Academic and the Non-University sectors. The General Pathology training programme for years has been considered one of the best of its kind in the country, and the Neuropathology training programme has attracted applicants from around the world, who have then gone on to important academic positions in the country. The Pathology training programme like those all around the country faces tremendous challenges due to the restrictions on positions and entry imposed by the Provincial governments. Residency numbers are at their lowest levels in 30 years in Canada and we are facing a significant shortage of academic pathologists imminently.

Since the 1950's, the Department, starting under the Headship of Dr. Robert More, has developed into an extremely strong academic unit. Although the Department is of relatively small size, in concert with the size of Queen's Medical School and the affiliated hospitals, it has achieved a level of academic excellence, far in excess of that expected for its numbers. The Department attracts external funding of approximately \$3.6 million annually, in competitive grants, a figure among the highest in the Medical School in absolute terms. (It should be pointed

out that this figure covers only those Faculty members having a Primary appointment in Pathology - those with joint appointments in Pathology whose home department is elsewhere are not included in these statistics). In comparison to other medical schools or on a FTE basis, this puts our Department at the pinnacle of departments across Canada. Pathology Department researchers have 4 times within the last 10 years won the University-wide Excellence in Research Award, a record unmatched by any other university department. Research groupings in the Department, in Cancer, Haemostasis, Amyloidosis, Neuroscience and Human Genetics have been well established, with multiple links to researchers in other departments across the university, and internationally. In this we have been the leaders in the development of highly productive research groups.

The service aspects of the Department take place mainly in the affiliated hospitals, Kingston General and Hotel Dieu. There is a complex administrative structure, which has traditionally encompassed 2 separate hospitals. In advance of the restructuring in the city of Kingston, a single Department sited primarily at Kingston General Hospital was developed in 1996. The clinical activities cover a wide range of specialist's and sub-specialist's expertise.

A major enterprise of a great practical and academic importance is the Clinical Laboratories of Eastern Ontario Regional Programme. This has been a concerted initiative over the last 15 years, involving the provision of laboratory services, expertise and increasingly education by the Queen's academic department to the hospitals in the region of South Eastern Ontario. This exercise is a novel one in Ontario with the potential to serve as a model not only for other Academic Pathology Departments across the Province, but for Clinical Departments as well.

The Department is thus fulfilling the mandate of the Dean's Vision Statement of the Medical School, in the Generation, Transmission and Application of knowledge. It has long concentrated on the training of excellent General Pathologists, while at the same time achieving international stature in the provision of selected sub-specialists' services. In the service and education sectors, the Department has served not only the entire local area, but has now embarked on an ambitious regional programme, taking into consideration the unique features of the South Eastern Ontario Health Sciences environment. In the field of research, or knowledge generation, international excellence has been achieved, through the formation of collaborative groups both within and outside the Department.

SUMMARY OF ALL ACTIVITIES (with a focus on clinical service)

The clinical service aspects of the Department resides predominantly in the Kingston General Hospital. In advance of the restructuring in the city of Kingston, an integrated Department sited at Kingston General Hospital was developed in 1996. Our activities require a wide range of specialist, sub-specialist, technical and managerial expertise and include:

Provision of accurate, useful and timely laboratory information to Clinical Services within the Kingston hospitals and region;

Individual and multidisciplinary team basic, translational and clinical research;

Teaching:

- Queen's Medical, Arts & Science, Graduate, Postdoctoral, Nursing and Rehabilitation Science students and Pathology residents
- Clinical staff and their residents through interdepartmental conferences
- Medical technologists from St. Lawrence College
- Fellows in Molecular Genetics and Cytogenetics
- Technologists in DNA Technology at Michener Institute

Medical direction of area hospital laboratories – Kingston General, Hotel Dieu, Napanee, Perth/Smiths Falls, St. Mary's, Ongwanada and MDS-Kingston;

Eastern Ontario Reference Laboratory - above hospitals and Hotel Dieu Hospital, Belleville, Brockville, Cornwall, Trenton, Ongwanada, Winchester, and from on April 1, 1999 onwards Campbellford, Cobourg/Port Hope, Peterborough, Lindsay and Lakeridge Health Corporation (Oshawa);

Regular extramural professional consultations including contractually defined Cytogenetics in Oshawa, Infection Control in Peterborough, and clinical chemistry in Quinte;

Regional Forensic Pathology Centre;

Ontario Regional Genetics Laboratory;

Community laboratory in conjunction with the Hospitals-in-Common Laboratory in Napanee and Perth/Smith Falls;

National Reference Laboratory for hemostasis testing for the Association of Hemophilia Centre Directors of Canada and surveillance information to the Canadian Blood Agency via that role;

Direct patient care - hemophilia, autologous blood transfusion. Participation by primary department faculty in the division of hematology and infectious diseases with on call ward and clinic coverage.

OUTREACH

a) Laboratory

A major enterprise of a great practical and academic importance is the Clinical Laboratories of Eastern Ontario Regional Programme. This has been a concerted initiative over the last 15 years, involving the provision of laboratory services, expertise and increasingly education by the Queen's academic department to the hospitals in the region of South Eastern Ontario. This exercise is a novel one in Ontario with the potential to serve as a model not only for other Academic Pathology Departments across the Province, but for Clinical Departments as well.

The Laboratory Outreach Program is operated by the Department of Clinical Laboratories of Kingston General Hospital, in conjunction with the Department of Pathology of Queen's University. The Program office and specimen reception area are located in Douglas Wing in Kingston General Hospital.

The Queen's University Department of Pathology has been providing a wide spectrum of outreach laboratory services for more than 30 years to a number of institutions (principally community hospitals) in southeastern Ontario and parts of northern Ontario (e.g. Moose Factory, Attawapiskat).

In 1987, in response to steady increases in referred-in service requests as well as to the growing needs of client institutions for more sophisticated laboratory testing, a distinct unit was created within the Clinical Laboratories of Kingston General Hospital. Its original purpose was to organize the pickup, reception and delivery of specimens and completed reports to contractual and non-contractual partners and clients. The Hotel Dieu Hospital joined in 1991 and we have operated such as a Kingston Hospitals Laboratory. Today, our staff have extended their activities into continuous quality improvement with performance of client satisfaction surveys and regular frequent interactions with clients to identify and address their needs and concerns. Additionally, the ongoing provision and co-ordination of Continuing Education services for clients is steadily increasing.

Most importantly for our clients, the lab outreach program provides a single entry point supported by a toll-free telephone number for all inquiries about pickups, results, lab specimen requirements or other needs, for clinicians, institutions and researchers alike. This ensures high quality, personalized service and eliminates the necessity to call several telephone numbers for a response to particular service issues.

Our client base has grown significantly with reference laboratory services provided to community hospitals located in Trenton, Belleville, Picton, Napanee, Perth, Smiths Falls, Brockville, Oshawa, Peterborough, Cobourg, Whitby, Bowmanville, Uxbridge, Port Perry and Lindsay. Laboratory services are also provided to Correctional Services Canada, MDS Laboratories, Canadian Medical Laboratories, Gamma/Dynacare Laboratories, Hospitals-In-Common Laboratory, Canadian Forces Base Kingston, Royal Military College, and a number of family physicians and dermatologists in the Kingston and Napanee communities. We also occasionally provide highly specialized testing services for a small number of American clients.

In addition to reference laboratory services, we offer medical/scientific direction to community hospital laboratories in Smiths Falls, Perth, Napanee, Belleville and Kingston (St. Mary's of the Lake Hospital and Ongwanada). Technical and laboratory management expertise are available to client institutions upon request.

Since 1991, remote printing of reports and on-line inquiry capability has been available for clients and currently, nine sites have electronic access to referred-in test results. The lab outreach program co-ordinates complete installation and technical support services for these systems, allowing same day test reporting performance for any client in our catchment area.

b) Education – Queen's Hight School Student Programs

During the past year, several outreach initiatives involving graduate students and Faculty members in the Department have continued. Some students as well as some members of the Department have been involved in a Cancer Conference presented to some of the local public

schools. This programme is organized by faculty and students in the Departments of Oncology, Biochemistry and Pathology. In addition, interested graduate students have been involved as judges for the Frontenac Lennox & Addington Science Fair. The Department of Enrichment Studies offers a Pathology course for gifted high school students across Canada. In the past, these two one-week sessions have run in April/May and offer high school students a good overview of Pathology. It has been the most popular course offered in Queen's enrichment for the last 2 years.

**PERSONNEL AWARDS
AND
SIGNIFICANT EVENTS**

PERSONNEL AWARDS AND SIGNIFICANT EVENTS

AWARDS

QUEEN'S UNIVERSITY PRIZE FOR EXCELLENCE IN RESEARCH

Dr. David Lillicrap received this 2001 award and presented a lecture entitled: "Molecular Medicine 2001: The Paradigm of Inherited Bleeding Disorders".

CIHR - CANADA RESEARCH CHAIRS

Dr. Susan Cole (Cancer Biology) and **Dr. David Lillicrap (Molecular Hemostasis)** were awarded Tier I Canada Research Chairs.

ONTARIO HEART & STROKE FOUNDATION

Dr. David Lillicrap has been an Ontario Heart and Stroke Foundation Career Investigator since 1995.

PMAC-HRF/MRC

Dr. Donald Maurice - 5th year of funding from a 5 year "Pharmaceutical Manufacturers Association-Health Research Foundation/Medical Research Council of Canada (PMAC-HRF/MRC) Career Research Award in Health Sciences (5 year salary award, \$65,000/annum)

HEART & STROKE FOUNDATION OF ONTARIO

Dr. Donald Maurice - 1st year of funding of a 5 year Career Investigator Award, Heart & Stroke Foundation of Ontario, (2001-2006, \$65,000/annum)

ROBERT PRENTICE AWARD - RESIDENT PATHOLOGY TEACHING

Pathology Residents were pleased to present **Dilys Rapson** with the Robert S.A. Prentice Award for excellence in teaching.

ONTARIO SOCIETY OF CLINICAL CHEMISTS

Mike Raymond received the award for outstanding contribution to clinical chemistry.

ASSOCIATION OF CANADIAN MEDICAL SCHOOLS

Dr. Lewis Tomalty received the John Ruedy Award for Innovation in Medical Education.

2001 R.S.A. PRENTICE AWARD

Dr. Jason Sack received this award for the best presentation by a pathology resident.

ROYAL COLLEGE 2001 REGIONAL AWARD FOR EXCELLENCE IN MEDICAL EDUCATION

Dr. W.E.N. Corbett retired Pathologist at Queen's University and OAP Emeritus members, is this year's winner of the Region 3 (Ontario) Award.

SIGNIFICANT EVENTS

Dr. John Rossiter received Tenure.

Drs. Mike Raymond and Caroline Rowlands were reappointed for a further 5 years; **Dr. Sherry Taylor** for a further 3 years.

Dr. Sandy Boag received Tenure and was promoted to Associate Professor.

Dr. Christine Collier was promoted to Associate Professor and was reappointed for a further 5 year term.

Dr. Susan Cole's research was featured in the Kingston Whig Standard in August 2001 and December 2001.

Dr. R. Kisilevsky was the American Cancer Society, Harry and Elsa Jiler International Visiting Scientist, University of Tennessee School of Medicine, Human Immunology and Cancer Program.

Dr. R. Kisilevsky was a Detweiler Travelling Fellow, RCPSC, University of Uppsala, Uppsala, Sweden (September 2001-2002).

Enrichment Mini-Course 2000

Drs. Jason Sack and Carla Cuthbert would like to formally thank the Department of Pathology for its continued support of the Pathology Enrichment Mini-Course. Again this year, "Pathology: An Inside Look" was the most popular course among forty-eight course options available.

Jason and Carla co-instructed the Pathology course the week of May 14th, 2001. They hosted sixty high-achieving Ontario high school students from both private and public school systems. These grade 11 through OAC students were enthralled with a variety of departmental tours, large and small group sessions, and a series of guest speakers. Nevertheless, without question, the highlight remained the opportunity to handle surgical specimens while sporting surgical gowns and gloves.

Dr. Sack, with a keen interest in medical education, wrote a curriculum document which outlined the ties between the course and the Ontario Ministry of Education's science curriculum, thereby ensuring a truly enriching experience for the students. As such, many students, independently and of their own initiative, prepared follow-up reports and projects which they presented to their fellow classmates at their respective high schools.

Dr. Cuthbert, with unwavering commitment, designed a web page to capture the memories of the week.

End-of-week student feedback forms overwhelmingly confirmed that the course not only promoted an appreciation for the realm of pathology but also fostered enthusiasm for science.


“It’s been a privilege and absolute pleasure to share our enthusiasm for pathology...again, ‘thank you’.”

--Jason & Carla

The 1st M. Daria Haust Visiting Lecturer

Dr. Kurt Benirschke, an Emeritus Professor of Pathology and Reproductive Medicine, University Medical Center, San Diego, California gave the First Haust Lecture. Dr. Benirschke was in the Department Monday and Tuesday, October 1st and 2nd and met with faculty and students. His lecture entitled “Challenges of the Pathology of Twinning” was on Monday, October 1, 2001 and was followed by a Reception held in Richardson Laboratories.

***UNDERGRADUATE, GRADUATE
AND
POSTGRADUATE
EDUCATIONAL PROGRAMS***



UNDERGRADUATE PROGRAMME

Phase I Pathology is given in the academic year from mid-November to mid-February to first year medical students. Enrolment is 90 students for 2001-2002.

Phase II Pathology is given after Phase I to 2nd year medical students but not in a Pathological Unit as such, but rather as a course combined with many other disciplines. Enrolment is 80.

Rehabilitation Medicine 225 (2001) The Department of Pathology continues its involvement in the Pathology Unit of this course. The Unit, which runs for five hours, contains sections on Inflammation & Tissue Healing (Dr. P. Manley), Neoplasia (Dr. T. Childs), Disturbances of Growth and Development (Dr. D. Dexter and Neuromuscular Tumours of the CNS (Dr. J. Rossiter). The Pathology section of the course is co-ordinated by Dr. Sandip SenGupta. Enrolment is 90 students.

Pathology 410/824 is a half credit course that runs in the Fall term and is co-ordinated by Dr. John Rossiter. It is offered to 4th year Life Sciences (non-medical) and graduate students. Forty-five undergraduate students and 8 graduate students enrolled in this course in 2001. Evaluation for undergraduate students includes a mid-term and final exam whereas graduate students, in addition to the exams, are expected to submit a term paper. A review of the course content, exams, marking system and student evaluations will take place in February/March 2001 by the Co-ordinator and lecturers.

Pathology 499 (formerly Path 420) is a full credit thesis project course co-ordinated by Dr. David Lillicrap and Dr. Robert Kisilevsky. Department faculty members supervise students on a year-long thesis project. Evaluations include a draft thesis introduction, seminar presentation, project defence, laboratory work evaluation and a written thesis. Enrolment is limited to approximately 12 students.

Pathology 430/826 is a half-credit course that is offered in alternate Winter terms (next offered in 2002-03). Drs. Robert Kisilevsky and David Lillicrap are Co-ordinators. Four diseases are covered in depth, examining the molecular events leading to the development of these disorders. Enrolment is limited to 12 with preference given to graduate students. Evaluation includes seminar presentations and written reports.

Life Sciences 422 is a half-credit, inter-disciplinary course offered through the Life Sciences Department in cellular / molecular neuroscience. The course is based on lectures and student seminars of selected readings. Sections are taught by faculty in Pathology (J. Rossiter), Physiology (K. Rose and G. Ross) and Anatomy & Cell Biology (C. Barajas-Lopez). Enrolment is approximately 25 students

GRADUATE PROGRAMME

The Graduate Programme in the Department of Pathology is administered by the Graduate Programme Committee. The Committee consists of four members of the Department, one of whom is designated Co-ordinator, plus the Head of the Department (Dr. Paul Manley) and two graduate student representatives *ex officio*. Dr. Peter Greer assumed the position of Co-ordinator of the Program and Chair of the Department of Pathology Graduate Committee as of July 1, 2001, taking over from Dr. Lois Mulligan (January 1 to June 30, 2001), who stepped down to Committee member. Faculty members from January to June 2001 were Drs. Susan Cole, Peter Greer and David LeBrun. Dr. Susan Cole resigned from the Committee as of June 30 and was replaced by Dr. Karen Harrison. The student representatives until July 1, 2001 were Annie Killoran and Glenn MacLean. Adina Vultur and Lee O'Brien assumed these positions for the 2001/2002 academic year. The Committee met on a monthly basis to make decisions on admissions; review student progress; discuss Comprehensive topics; review membership of Comprehensive, Master's and Doctoral examining committees; set stipend rates; and recommend students for scholarships and awards.

Thirty-two students were registered during the 2001 calendar year. Registration was equally distributed between the Master's and PhD Programmes. Melissa Carter, Annie Killoran, Eva Lin and Jennifer Struthers, all Master's students, defended their theses in 2001. PhD students who defended their comprehensive proposals were Dawei Zhang Lee Fraser and Suzan Abu-Abed. Glenn MacLean and Brandy Hyndman were successful in the defence of their Mini-Master's theses and were promoted directly to the PhD Program.

Department of Pathology graduate students were very successful in competitive award competitions in for the 2001/02 academic year. Ontario Graduate Scholarships were awarded to Deborah Greer, Glenn MacLean and Peter Truesdell. Deborah Greer was awarded an NSERC Fellowship for two years (her OGS was reverted), and Adina Vultur continued in her second year of NSERC funding. The National Cancer Institute of Canada continued to fund Bob St. Onge. Suzan Abu-Abed received a Medical Research Council studentship to support her research. Ontario Graduate Scholarships in Science & Technology were awarded to Fiona Grant and Brian Brown. Kevin Weigl and Lee O'Brien successfully competed for McLaughlin Scholarships. A Dean's Visible Minority Award was given to Angela Hui.

Approximately 100 graduate studies applications were distributed in 2001 either by mail or in person. Many more enquiries were received and dealt with through electronic mail. Twenty-five applications were received and processed resulting in 16 students being conditionally accepted; and of those, nine new students were accepted into research programs by supervisors in 2001.

RECRUITMENT INITIATIVES:

The Department of Pathology is represented at the Life Sciences careers evening in January. Many 3rd and 4th year students indicate their interest in 4th year projects or graduate studies at this event. In addition, the Department has a limited budget to invite excellent students to visit the Department from other centres. The Department of Pathology Graduate Studentship Award continues to be available to compete for recruitment of exceptional candidates. Together, these initiatives have improved the

profile of the Department of Pathology in the Life Sciences programme and recruitment for graduate studies.

OUTREACH:

During the past year, several outreach initiatives involving graduate students and Faculty members in the Department have continued. Some students as well as some members of the Department have been involved in a Cancer Conference presented to some of the local public schools. This programme is organized by faculty and students in the Departments of Oncology, Biochemistry and Pathology. In addition, interested graduate students have been involved as judges for the Frontenac Lennox & Addington Science Fair. The Department of Enrichment Studies offers a Pathology course for gifted high school students across Canada. These two one-week sessions run in April/May and offer high school students a good overview of Pathology. The course will be run again in 2003.

GRADUATE STUDENT PRESENTATIONS:

Graduate students were honoured by invitations to present their research at national/international conferences. These are outlined below:

- | | |
|----------------|--|
| Brian Brown | 4 th Annual Meeting of the American Society of Gene Therapy.
June 2001
<i>Targeting a Single Nucleotide Exchange Reaction by Use of a Small Oligonucleotide in Mammalian and Yeast Cell Free Extracts</i>
43 rd Annual Meeting of the American Society of Hematology.
December 2001
<i>Helper-dependent Adenovirus Delivery of a Canine F.VIII B-domain Deleted Transgene in Murine and Canine Models of Hemophilia A</i> |
| Brandy Hyndman | 44 th Annual Meeting, Canadian Federation of Biological Societies,
Ottawa, Ontario, June 21-23, 2001
<i>Screening in Yeast for E2a-Interactive Proteins Using the Ras Recruitment System</i> |
| Adina Vultur | 17 th Annual Meeting on Oncogenes. Frederick Maryland
<i>Gap Junctional, Intercellular Communication in Urethane-induced Tumors in A/J Mice</i>
4 th Annual Meeting for Research Trainees, Queen's University
<i>STAT3 Activation in Cells Expressing the Large Tumor Antigen of Simian Virus 40</i> |
| Dawei Zhang | 3 rd FEBS Advanced Lecture Course Gosau, Austria. March, 2001.
<i>(ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease)</i> |

RESEARCH SEMINAR SERIES

The Department of Pathology Research Seminar Series is held every Tuesday during the academic year in Richardson Amphitheatre at 4:00 p.m. Speakers include Graduate Students, Pathology Faculty, and invited speakers from both within and outside of Queens University. The following seminars were presented by invited speakers and graduate students in 2001.

Invited Speakers:

- January 12, 2001 **Dr. Christian Naus**, Dept. of Anatomy & Cell Biology, University of Western Ontario
Functions of intercellular communication in neurons and astrocytes
- January 23 **Dr. Doug Munoz**, Department of Physiology, Queen's University
Using eye movements to probe brain function and dysfunction
- March 27 **Dr. Gergely Lukacs**, Cell & Lung Biology, Hospital for Sick Children Research Institute
Sorting determinants of the cystic fibrosis transmembrane conductance regulator (CFTR) at the ER and cell surface
- April 3 **Dr. Ioanna Maroulakou**, Department of Medicine, Medical University of South Carolina
Molecular mechanisms for mammary gland development in breast cancer
- April 10 **Dr. Paul Fraser**, Dept. of Biophysics, University of Toronto and The Centre for Research in Neurodegenerative Diseases
Demented proteins in Alzheimer's disease
- April 24 **Dr. Bosco Chan**, University of Western Ontario, Robarts Research Inst.
Signal regulation of cell movement in rat pheochromocytoma PC12 cells
- May 14 **Dr. Jonathon Coren**, Southwestern Oklahoma State University
Construction of an improved PAC vector system for functional genetic studies
- May 15 **Dr. Joseph Torchia**, Cancer Research Labs, London Regional Cancer Ctr.
New insights into the regulation and mechanism of nuclear receptor coactivators
- May 22 **Dr. William Skarnes**, Dept. of Molecular and Cell Biology, University of California
Gene trapping approaches for the functional analysis of genes in mice

Graduate Students

- January 16, 2001 **Ms Melissa Carter**, Dr. Mulligan's Lab
Of Mice and Men: Comparative genomic mapping of RET and its 3' splice variants
- Ms Brandy Hyndman**, Dr. LeBrun's Lab
Identification and characterization of E2a-interactive proteins

- January 30 **Ms Fiona Grant**, Dr. Lillicrap's Lab
Analysis of the murine immune response evoked by gene therapy for hemophilia A
- Ms Eva Lin**, Dr. Elliott's Lab
The role of HGF and the cell adhesion complex in c-Src tyrosine kinase activation in mammary carcinoma cells
- February 27 **Ms Lee O'Brien**, Dr. Lillicrap's Lab
Investigation of the molecular pathogenesis of T type IIa von Willebrand's Disease
- March 6 **Ms Diana Naumovski**, Dr. Mulligan's Lab
Transcriptional regulation of the GFR α -1 gene and its role in human disease
- Ms Sarah Kinkley**, Dr. Kisilevsky's Lab
Acute phase serum amyloid A: tracing its path through the macrophage following its uptake
- March 13 **Ms Suzy Abu-Abed**, Dr. Petkovich's Lab
Analyzing the Cyp26A1 null mutant mouse
- March 20 **Ms Adina Vultur**, Dr. Raptis' Lab
Effects of SVLT on the STATs pathway
- May 1 **Ms Deborah Greer**, Dr. Davey's Lab
DNA damage response of G2 checkpoint protein hRad9
- May 8 **Mr. Martin Kang**, Dr. Davey's Lab
The genetic and biochemical properties of UV damage endonuclease, a DNA repair enzyme from Schizosaccharomyces pombe
- October 16 **Mr. Yotis Senis**, Dr. Greer's Lab
Platelets: A novel model for studying the physiological functions of the Fps proto-oncogene and its family member Fer
- October 30 **Mr. Glenn MacLean**, Dr. Petkovich's Lab
Cyp26B1, a retinoic acid metabolizing cytochrome P450: Expression during murine embryogenesis
- November 20 **Mr. Ted Wright**, Dr. Elliott's Lab
Hepatocyte growth factor interaction with its receptor MET in breast cancer: Development & screening of potential antagonists
- December 4 **Ms Brandy Hyndman**, Dr. LeBrun's Lab
Identification and characterization of E2a-interactive proteins
- December 11 **Mr. Bob St. Onge**, Dr. Davey's Lab
Dialing 9-1-1? Elucidating the role of hRad9 protein phosphorylation in checkpoint activation and cellular responses to DNA damage

COUNCIL OF ONTARIO UNIVERSITIES PERIODIC APPRAISAL

In July 1996, the Appraisals Committee of the Council of Ontario Universities evaluated the Master's and Doctoral programs in the Department of Pathology. Periodic appraisals of the graduate programs are undertaken at seven year intervals by the Ontario Council on Graduate Studies. A detailed brief, outlining all aspects of the Graduate Programme in the Department was prepared and submitted to the School of Graduate Studies and Research in May 1996, for final submission to the Council of Ontario Universities. In February 1997, the Department was informed that the Appraisals Committee had

approved the MSc/PhD Programme in Pathology with an "A" rating. The next accreditation will be in 2003.

GRADUATE COURSES

The following graduate courses are offered in the Department of Pathology:

Cancer Biology - Pathology 823

This course is co-ordinated by Dr. Bruce Elliott. Essential questions in clinical and basic oncology are introduced and discussed. The course is offered in alternate years. Enrolment is limited to 20 students or less. It was offered in the 2000/20001 academic year.

Graduate Pathology for Non-Medical Students - Pathology 824/410

The course co-ordinator is Dr. John Rossiter. This course provides a general introduction to the pathological processes involved in common human disease. The course is offered annually in the Fall in conjunction with Path 410. Eight graduate students were enrolled in the Fall term of 2001.

Human Genetics - Pathology 825

The course co-ordinator is Dr. Lois Mulligan. Molecular mechanisms responsible for human disease are discussed with examples of diagnostic studies. The course is offered in alternate years in the Winter term. In the Winter of 2001-2002, seven students were enrolled.

The Molecular Basis of Disease - Pathology 826

The course co-ordinators are Drs. Robert Kisilevsky and David Lillicrap. This graduate course is offered alternate years; enrolment is limited to 15 students or less. The course reviews in detail the pathogenic details of four specific areas of tumour disease. The course was offered in the Winter term 2000-2001. Eight students were enrolled.

DEPARTMENT OF PATHOLOGY GRADUATE STUDENTS 2001 (Calendar Year)

Student Name	Program	Start Date	Supervisor	
Abu-Abed, Suzan	PhD	09/98	Dr. Petkovich	Defended Comps 19/04
Almquist, Kurt	PhD	09/95	Drs. Cole/Deeley	
Brown, Brian	PhD	09/00	Dr. Lillicrap	
Carter, Melissa	MSc	09/99	Dr. Mulligan	Defended MSc 20/08/2
Davidson, Chris	PhD	09/97	Dr. Kisilevsky	Inactive Winter and
Fraser, Lee	PhD	09/98	Dr. Davey	Defended Comps 26/02
Greer, Deborah	PhD	09/00	Dr. Davey	
Grant, Fiona	MSc	09/00	Dr. Lillicrap	
Hui, Angela *	MSc	09/01	Dr. Elliott	
Hyndman, Brandy	PhD	05/01	Dr. LeBrun	Defended MiniMSc 23/04
Kang, Martin	MSc	09/99	Dr. Davey	
Killoran, Annie	MSc	09/99	Dr. Lillicrap	Defended MSc 04/09
Kinkley, Sarah	MSc	09/00	Dr. Kisilevsky	
Lin, Catherine *	MSc (Prob)	09/01	Dr. Petkovich	
Lin, Eva	MSc	09/00	Dr. Elliott	Defended MSc 30/11
MacLean, Glenn	PhD	09/99	Dr. Petkovich	Defended Mini-MSc 25/04
Naumovski, Diana	MSc	09/00	Dr. Mulligan	Withdrew 31/08
O'Brien, Lee	PhD	09/00	Dr. Lillicrap	
St. Onge, Bob	PhD	9/99	Dr. Davey	
Senis, Yotis	PhD	05/96	Dr. Greer	
Shaw, Julie *	MSc	09/01	Dr. Mulligan	
Situ, Donna *	MSc	09/01	Dr. Cole	
Smith, Patrick *	MSc	09/01	Drs. Greer/Anatassiades	
Struthers, Jennifer	MSc	09/98	Dr. Khalifa	Completed MSc 29/05
Truesdell, Peter	PhD	09/99	Dr. Greer	
Vultur, Adina	PhD	09/00	Dr. Raptis	
Weigl, Kevin	PhD	09/99	Dr. Cole	
Wojcik, Joanna *	MSc	09/01	Dr. Elliott	
Wong, Jimson *	MSc	09/01	Dr. Davey	
Wright, Ted *	PhD	09/01	Dr. Elliott	
Yome, Julie *	MSc	09/01	Dr. Mulligan	
Zhang, Dawei	PhD	09/98	Dr. Deeley	Defended Comps 22/05

* New students in September 2001

POSTGRADUATE MEDICAL EDUCATION

Dr. Caroline Rowlands is the Director of the Postgraduate Education Programme in the Department of Pathology and also the Programme Director of Anatomical and General Pathology. Dr. John Rossiter is the Programme Director of Neuropathology. The Programme Director of Hematopathology is Dr. Dilys Rapson.

Resident Appointments

July 1, 2000 - June 30, 2001

Dr. Tim Childs	PGY-3
Dr. Patricia Farmer	PGY-2
Dr. Jason Sack	PGY-3

July 1, 2001-June 30, 2002

Dr. Tim Childs	PGY-4
Dr. Patricia Farmer	PGY-3
Dr. Mohammed Khodabandehloo	PGY-1
Dr. Benjamin Mathew	PGY-1
Dr. Jason Sack	PGY-4

AWARDS

Dr. Jason Sack received the RSA Prentice Award for [best presentation by a pathology resident].

LECTURES/PRESENTATIONS

Tim Childs

- 1) "Cytokeratin Immunoreactivity Patterns and More", Pathology Grand Rounds, January 11, 2001.
- 2) "Practical Solutions for Pathology", Pathology Grand Rounds, September 6, 2001.

Patricia Farmer

- 1) "Colorectal Cancer Review", Pathology Grand Rounds, February 22, 2001.
- 2) "Mast Cell Disorders – A Review", Pathology Grand Rounds, November 1, 2001.

Jason Sack

- 1) "Portable I.C.E.", Pathology Grand Rounds, March 22, 2001.
- 2) In conjunction with Dr. Carla Cuthbert, "Pathology: An Inside Look", Pathology Grand Rounds, July 12, 2001.

ACCREDITATION - ROYAL COLLEGE OF PHYSICIANS AND SURGEONS

The Royal College of Physicians and Surgeons Accreditation of the Anatomical Pathology, General Pathology, Hematopathology and Neuropathology Postgraduate Programs took place in October 1999. RCPS accreditation status for the Queen's Pathology programs is as follows: AP - full approval; GP - inactive; HP - inactive; NP - inactive. The inactive designation reflects that at the time of the survey no residents were registered in these programs. An internal review of an active program by the PGME Committee is mandated within one year of program re-activation. With Patricia Farmer entering the GP Program in July 2000, an internal review was held in August 2001. The Program received full approval.

The next accreditation review is scheduled for 2005. If a training program is still inactive at this time, accreditation can be withdrawn.

CANADIAN RESIDENT MATCHING SYSTEM (CaRMS)

This year's CaRMS applicants to the pathology residency training programs at Queen's (one position available) totalled 15. Of these, 13 applicants attended onsite interviews held during January 2001 and a rank order list was subsequently submitted to CaRMS.

We were successful in filling our one "lab medicine" position. Dr. Benjamin Mathew, a graduate of the University of Manitoba, began the Neuropathology Program in July 2001. Dr. Mohammed Khodabandehloo began residency training in Anatomical Pathology July 2001. He was matched to Queen's Pathology through the Ontario International Medical Graduate program (2nd iteration of the OIMG "mini-match"). He is a graduate of Tabriz University (1991) in Iran and emigrated to Canada in 1996.

	AGENCY	AMOUNT/Y R	DURATION	TITLE OF RESEARCH PROJECT
Feilottter A. Boag	KGH Clare Nelson	\$9,293	2001-2002	Gene Expression Profiling Studies in P Tumouragenesis
Cole & R. Deeley	MRC	\$106,500	3 years	Cellular and molecular studies of MRP- multidrug resistance
Cole & R. Deeley	CIHR	\$47,445	2001-2006	Investigations of MRP-Mediated Drug Resistance and Xenobiotic Transport
Cole & 14 others	CIHR	\$14,292	2001-2004	Maintanence of Fluorescence Activated Sorter and Confocal Microscope: A Mt Facility
Cole, R. Deeley & ovich	NCIC (Program Project Core)	\$67,098	2000-2003	Molecular Mechanisms of Drug Resista
ole	NCIC	\$170,558	2000-2003	Investigations of Topoisomerase II in D Resistance
ole	Proctor & Gamble, USA	\$57,960	2001-2002	Contract
ole	CFI	\$124,866	2001	Infrastructure
ole	CIHR		2001-2008	Canada Research Chair (Tier I)
Cole & R. Deeley	NCIC	\$204,611	2000-2003	Multidrug Resistance Conferred by MR
Collier, J. Heaton, mond, A. Morales &	KGH, Hospital Research Grant	\$9,855	2001	Free Testosterone: Which Method Pro Best Clinical Correlation?
ott, J. van Eyk, R. C. Collier, D. nio	MOH & Long-Term Care: Emergency Health Services Research Grant	\$43,900	2000-2002	Novel Troponin I modification products predictors of cardiac events in emerger patients.
Deeley & S. Cole	NCIC	\$204,610	2000-2003	Multidrug resistance conferred by MRP
Deeley, T. Flynn others	CFI/OIT/Industry in Kind	\$1,792,513	2000-2005	Protein Function Discovery
Deeley, J. Pater & 8	OIT	\$4,700,000		Queen's Cancer Research Institute
liott				
liott Postdoctoral hip for new ent	USA/MRMC	\$43,047	2 years remaining	Signal transduction in regulation of aut HGF expression in cancer metastasis.
liott (Studentship right)	USA/MRMC	\$23,748	2002-2003	Identification of hepatocyte growth fact autocrine loops in breast carcinomas: F targets for therapeutic intervention
liott	Genentech (Contract)	\$8,000	2001-2002	Development of peptide antagonists to hepatocyte growth factor as a novel ap therapeutic intervention in breast cance
liott	CIHR	\$63,593	1999-2002	Role of HGF and the cell adhesion con survival and metastasis of lung carcino
elliott & S. ta	Pathology Clinical Trust Fund	\$6,608	2001	Breast Cancer Risk in Relation to HER Oncoprotein expression and exposure Contraceptives and PCBs

	AGENCY	AMOUNT/Y R	DURATION	TITLE OF RESEARCH PROJECT
Elliott & S. ta	Clare Nelson Bequest	\$8,909	2001	Breast Cancer Risk in Relation to HER Oncoprotein expression and exposure Contraceptives and PCBs
Fletcher, R. Reid, D. t	MRC	\$93,000	1999-2001	Novel gynecological Applications for Photodynamic Therapy - (I act as the F Consultant)
Greer	NCIC	\$150,000	2001-2006	A molecular and genetic analysis of the proto-oncogene
Greer	CIHR	\$127,873	2001-2004	A molecular and genetic analysis of the <i>fer</i> gene.
A. Greer & L.	NCIC	\$45,445	2001-2004	Investigating Functional Differences Be RET Receptor Isoforms in Cell Growth Development
Greer & L. Mulligan	CIHR	\$135,612	2001-2004	Investigating Functional Differences Be RET Receptor Isoforms in Cell Growth Development
Harrison	Pathology Clinical Trust Fund	\$9,630	2001-2002	Genetic Studies of Sirenomelia and Holoprosencephaly
Harrison & Greg	KGH Research Fund Competition	\$10,000	2000-2001	Fluorescent in situ hybridization for the detection of prenatal aneuploidy
MacKenzie and K. i	Angada Foundation	\$3,045.93	2000-2001	Evaluation of familial developmental disability molecular cytogenetic screening for cryptic chromosome rearrangements.
Harrison & D.	Pathology Clinical Trust Fund	\$9,982	2000-2001	Detection of genomic changes in mantle cell lymphoma.
Matthews & K. i	KGH Clare Nelson Bequest Fund	\$4,984	2000-2001	Molecular cytogenetic identification of chromosomal abnormalities in multiple myeloma.
Harrison et al	OAML Small Grant Program	\$34,907.86	2001-2002	Molecular Cytogenetic Evaluation of Structural Duplications Using High Resolution FISH
Hurlbut & W. n	ACG Clinical Research Fund	\$28,836	2000-present	Mast Cells in Gastroesophageal Reflux Disease
Kisilevsky	MRC	\$104,000	1998-2001	Amyloidogenesis: An analysis of the cellular factors in an experimental murine model
Kisilevsky & W.	Inst. for Study of Aging, USA	\$120,000	2000-2002	Novel glycosaminoglycan precursors as potential amyloid agents.
Kisilevsky, W. and J. Kennedy	Bill & Melinda Gates Foundation	\$255,000	2000-2003	A novel approach to anti-malarial therapy
Kisilevsky	CIHR	\$159,000	2001-2006	Amyloidogenesis: An Analysis of the Cellular Factors in an Experimental Murine Model
Kisilevsky & S.	Botterell Foundation	\$4,500	2000-2001	High resolution Ultrastructure of Perivascular Beta-amyloid Deposition in AD
LeBrun	CRS	\$113,996	2001-2003	Transcriptional Repression of AML1/Runx1 by the Leukemogenic Transcription Factor PBx1
LeBrun, J. Matthews & Shepherd	KGH Clinical Research Grant	\$9,293	2001-2002	Developing a Blood Test for the Distinction of CLL from mantle Cell Lymphoma
LeBrun	NCIC	\$ 44,995	2000-2001	Mechanisms of Oncogenesis by E2a-P

	AGENCY	AMOUNT/Y R	DURATION	TITLE OF RESEARCH PROJECT
èBrun	CIHR/MRC	\$277,380	2000-2003	Elucidation of Protein-Protein Interactions Involving the N-terminus of E2a
Illicrap	MRC/CIHR	104,119	1998-2002	Characterization of Mechanisms Regulating Developmental Expression of Coagulation Factor IX
Illicrap	Bayer	\$100,000	1999-2001	Studies of novel therapeutic strategies for hemophilia A in a canine model
Illicrap	Canadian Hemophilia Society	\$50,000	1999-2001	Evaluation of a Model System for the Site Specific Correction of Hemophilic Mutations
Illicrap	LCDC	\$150,000	2000-2003	A National Hemophilia Mutation Testing Program
Illicrap	HSFO	\$88,944	2000-2005	Influence of Genotype and Environment on Endothelial Cell Expression of vonWillebrand Factor
Illicrap	Genetics Institute	\$93,439	2000-2001	The influence of Factor VIII Genotype on the incidence of inhibitor development with recombinant factor VIII product
Illicrap	CIHR	\$80,908	2000-2004	The molecular genetic basis of type 1 von Willebrand disease
Illicrap	Bayer/CBS Partnership Fund	\$86,379	2000-2002	Inhibitor development following factor VIII therapy: Evaluation of a mouse model
Illicrap	HSFO	\$53,500/yr	5 years	Career Investigator Award
Illicrap	Centeon/CBS	\$17,378/yr	1 year	Polymorphisms of the Glycoprotein Ib and their influence on bleeding manifestations and diagnosis in type 1 von Willebrand disease
Illicrap, M. G., M. Koschinsky, D. Maurice and D. G.	Heart and Stroke Foundation of Ontario	\$112,200	2000-2005	Collaborative studies of hemostasis, fibrinolysis and vascular cell growth and function"
Illicrap	Ipsen Inc.	\$189,004	2001-2002	In vivo Studies in Hemostatic Efficacy and Safety of a Recombinant Porcine Factor VIII Concentrate
Illicrap	Bayer Inc.	\$192,458	2001-2002	Hemostatic Effects of a Liposomal Preparation of the Recombinant Factor VIII Product Kogenate FS
Illicrap	Pathology Clinical Trust fund	\$10,000	2001-2002	Comparative Studies on Demyelination and Remyelination in the ND4 Transgenic Mouse Model
Illicrap	NCIC Contract	\$54,000	1992-present	Collection, Verification and Dissemination of Tissue Sections of Study Material
Illicrap	HSFO	\$75,700	1999-2003	Cyclic Nucleotide Phosphodiesterases in Arteries
Illicrap	CIHR	\$54,000	2001-2002	Role of PDE3 and PDE4 in Diabetes-Associated Cardiovascular Disease
Illicrap & M. G., et al	HSFO	\$147,000		Collaborative Studies of Hemostasis, Fibrinolysis and Vascular Cell Growth and Function
Illicrap	HSFO	\$8,000	1 year	Visiting Scientist Award
Illicrap	HSFO	\$92,000	2001-2002	Cyclic Nucleotide Phosphodiesterases in Arteries

	AGENCY	AMOUNT/Y R	DURATION	TITLE OF RESEARCH PROJECT
aurice & K.	HSFO	\$88,216	2001-2002	Heme Supply for Hemoenzymes Assoc with Vascular Relaxation
rossiter, L. Mulligan er	CIHR	\$136,802	2001-2004	Investigating Functional Differences Be RET Receptor Isoforms
rossiter	Ontario Neurotrauma Foundation	\$43,585	2000-2001	Detection of diffuse axonal injury in hur cases of very short post-injury survival immunohistochemistry
owlands	Pathology Clinical Trust Fund	\$4,793	2000-2001	Role of Altered Apoptotic Control in the Pathogenesis of Psoriasis
onson, S. ta, W. Hanna, E.	Canadian Breast Cancer Research Initiative	\$56,576	1999-2001	Steroid receptor content of benign brea epithelium and breast cancer risk
hepherd, K. d, P. Watson, M.	NCIC	\$47,399	1977-2001	Clinical Trials Group "A Tumour, Tissue Clinical Data Bank for Breast Cancer P Participating in NCIC CTG Clinical Tria
hepherd, T. et al	CBCRI	\$300,000	1999-2002	Clinical Trials Group "A Randomized T Regional Radiotherapy in Early Breast
hepherd, K. d, et al	CBCRI	\$100,000	1999-2002	The Role of Neu/Erb B-2 as a Predictiv for Differential Response to Adjuvant Chemotherapy and Tamoxifen
hepherd, J. Pater,	NCIC	\$3,100,000	1999-2004	NCIC Clinical Trials Group
hepherd	Parmacia, Bristol Myers, Squibb, Ortho Biotech, Amgen, Janssen	\$2,131,000 US \$2,525,000	2000-2005	A Phase III Adjuvant Trial of Sequence GCSF followed by Taxol vs. Sequence followed by Taxol vs. CED as Therapy Premenopausal Women and Post Men Women less than 60 years of age who Potentially Curative Surgery for Node F High Risk Node Negative Breast Canc
aylor	KGH Foundation	\$8,724	2001-2002	Development of a Method for the Study Methylation Patterns of the Human Gei
aylor	Pathology Clinical Trust Fund	\$9,630	2001-2002	Genetic Studies of Sirenomelia and Holoprosencephaly
omalty	McGraw Hill Publishers	\$27,000		Development of Microbes in Motion III
outman	Health Canada	\$30,000	2000-2001	Resources for Infection Control in Hosp
outman	Health Canada	\$1,500	2000-2001	National MRSA Surveillance Project
outman	Health Canada	\$3,000	2000-2001	National CSF Shunt Infection Surveillai
Zoutman, M. Loeb, er and A. Simon	US DHHS	\$239,000	2000-2002	Implementation and assessment of a D and Treatment Algorithm for Urinary Tr Infections in Long Term Care Facilities
Zoutman & D.	Gov. of Canada, Dept. of National Defense	\$438,358	2001-2003	Health Outcomes Study
outman	Pathology Clinical Trust	\$10,000	2001-2002	Impact of Prescriber Information Feedb Antibiotic Resistance Utilization at St. M the Lake Hospital
outman	Pfizer Pharmaceuticals	\$10,000	2000-2001	Antibiotics in Moderation (AIM) Clinical

	AGENCY	AMOUNT/Y R	DURATION	TITLE OF RESEARCH PROJECT
outman	Bristol Myers Squibb Clinical Research	\$9,000/case	2001-2002	Multicenter Randomized Controlled Trial 283756 in Treatment of Intra-Abdominal Infection
outman	Health Canada	\$25,000	2001-2003	Canadian Surgical Wound Infection Sur- vey Project
outman	CIDA	\$2,043,420	2001-2004	Strengthening Essential Public Health in the Balkans

**VISITING LECTURERS
2001**

INVITED SPEAKERS

NAME	TITLE	DATE
Dr. Christian Naus Professor, Dept. of Anatomy and Cell Biology, University of Western Ontario, London, ON	Functions of Intercellular Communication in Neurons and Astrocytes	January 12, 2001
Dr. Doug Munoz Professor, Dept. Of Physiology, Queen's University	Using Eye Movements to Probe Brain Function and Dysfunction	January 23, 2001
Dr. Gergely L. Lukacs Cell & Lung Biology, Hospital for Sick Children Research Institute Anatomic Pathologist, Laboratory, Saskatoon City Hospital, Saskatoon, Saskatchewan	Sorting Determinants of the Cystic Fibrosis transmembrane Conductance Regulator (CFTR) at the ER and Cell Surface	March 27, 2001
Dr. Ioanna Maroulakou Assistant Professor of Medicine, Medical University of South Carolina	Molecular Mechanisms for Mammary Gland Development in Breast Cancer	April 3, 2001
Dr. Paul Fraser Associate Professor, Dept. of Biophysics, University of Toronto and The Centre for Research in Neurodegenerative Diseases	Demented Proteins in Alzheimer's Disease	April 10, 2001
Dr. Bosco Chan Associate Professor, University of Western Ontario, Research Scientist, Robarts Research Institute	Signal Regulation of Cell Movement in Rat Pheochromocytoma PC12 Cells	April 24, 2001
Dr. Jonathon Coren Southwestern Oklahoma State University	Construction of an Improved PAC Vector System for Functional Genetic Studies	May 14, 2001
Dr. Joseph Torchia Cancer Research Laboratories, London Regional Cancer Centre	New Insights into the Regulation and Mechanism of Nuclear Receptor Coactivators	May 15, 2001
Dr. William C. Skarnes Department of Molecular and Cell Biology, University of California, Berkeley, California	Gene Trapping Approaches for the Functional Analysis of Genes in Mice	May 22, 2001
Dr. Greg Ross Assistant Professor, Dept. of Physiology, Queen's University	A New Role for the Common Neurotrophin Receptor p75 in Neuronal Death Associated with Alzheimer's Disease	September 11, 2001

Dr. Kurt Benirschke Emeritus Professor of Pathology & Reproductive Medicine, University Medical Center, San Diego, California	Challenges of the Pathology of Twinning (M. Daria Haust Lectureship Fund)	October 1, 2001
Dr. Mike Nesheim Professor, Department of Biochemistry, Queen's University	Thrombin Activatable Fibrinolysis Inhibitor	October 2, 2001
Dr. Brian Cummings Dalhousie University Halifax, NS	Acute Myelogenous Leukemia Presenting in Glycogen Storage Disease 1b	October 17, 2001
Dr. Holly Brown AP, Peterborough Regional Health Centre	Sentinel Lymph Node Biopsy in Malignant Melanoma	October 25, 2001
Dr. Jennifer MacKenzie Department of Pediatrics, Queen's University	Advances in Enzyme Replacement Therapy for Inborn Errors of Metabolism	October 31, 2001
Dr. Barbara Vanderhyden Corinne Boyer Chair in Ovarian Cancer Research, University of Ottawa	Characterizing the Ovarian Surface Epithelium and Targeting Gene Expression to Generate Mouse Models of Ovarian Cancer	November 6, 2001
Dr. Rashmi Kothary Associate Director, Ottawa Health Research Institute, Senior Scientist, Molecular Medicine Program	Cytoskeletal Crosslinker Proteins and their Role in Maintaining Cytoarchitectural Integrity	November 13, 2001
Dr. Philippe Gros Department of Biochemistry, McGill University	Nramp Proteins, Metal Transport and Resistance to Infections	November 27, 2001
Dr. Cynthia Forster-Gibson Dept. of Family Medicine, Queen's University	The Smith Magenis Syndrome – from Infant to Senior Citizen	November 28, 2001
Dr. Richard J. Beninger Departments of Psychology and Psychiatry, Queen's University	Dopamine Signalling and the Mechanisms of Reward-Related Learning	December 18, 2001

**SENIOR STAFF
DEPARTMENT OF PATHOLOGY
AND QUEEN'S UNIVERSITY
LECTURES**

**SENIOR STAFF
DEPARTMENT OF PATHOLOGY, QUEEN'S UNIVERSITY
AND KGH
LECTURES**

Dr. S. Boag

- 1) "A Digital Photography Survival Toolkit", Pathology Grand Rounds, 1 February 2001.

Dr. C. Collier

- 1) "Pondering the Unknown: QMPLS", Pathology Grand Rounds, 27 September 2001.

Dr. R. Deeley

- 1) Department of Oncology, Kingston Regional Cancer Centre, Grand Rounds, November 2001.

Dr. B. Elliott

- 1) Symposium on Biology of Cellular Invasiveness, "Role of Scatter Factor/HGF Autocrine Loops in Epithelial Mesenchymal Transition and Cancer", Queen's University, June 1, 2001. (Invited Lecturer)

Dr. H. Feilotter

- 1) "The Queen's Microarray Facility: Who, What, When, Where, Why and How-to", Department of Pathology Seminar Series, 20 June 2001.
- 2) "Damn the Hypotheses – Full Speed Ahead", Pathology Grand Rounds, 7 June 2001

Dr. A. Fletcher

- 1) "On the Frontiers of Borderline Ovarian Surface Epithelial-Stromal Tumours", Pathology Grand Rounds, 28 June 2001.

Dr. P. Greer

- 1) Department of Physiology, Queen's University, 2001.
- 2) Department of Oncology, Queen's University, 2001

Dr. K. Harrison

- 1) "Presentation of Somatic Cancer Genetic Testing Algorithms – Clinical and Laboratory Implications". Pathology Grand Rounds, 1 March 2001.

Dr. D. Hurlbut

- 1) "New GI Procedures and Techniques: Clinicopathologic Implications", Pathology Grand Rounds, 13, December 2001.
- 2) "DNA Fingerprinting in Forensic and Clinical Pathology", Pathology Grand Rounds, 25 January 2001.
- 3) Surgical Suites Education Day, KGH, "Surgical Specimens and Pathology – What the OR Needs to Know", March 30, 2001.

Dr. R. Kisilevsky

1) "Role of Serum Amyloid 'A' in Cholesterol Mobilization from Sites of Tissue Injury", Pathology Grand Rounds, 14 June 2001.

Dr. D. LeBrun

1) "Discovering New E2A – Interactive Proteins", Pathology Grand Rounds, 11 October, 2001.

Dr. D. Lillierap

1) "Sequencing of the Human Genome: Holy Grail or Holy Smoke (and Mirrors)", Pathology Grand Rounds, 5 April 2001.

Dr. S. Ludwin

1) "Vascular Neogenesis in Diseases of the Nervous System", Pathology Grand Rounds, 29 November 2001.

2) "Clinical and Experimental Studies in Multiple Sclerosis", Pathology Seminars Series, 6 February 2001.

Dr. P. Manley

1) "Inflammatory Insights", Pathology Grand Rounds, 12 April 2001.

Dr. D. Rapson

1) "An Old Dog with New Tricks – Waveform Profiles in the PTT. What is New?", Pathology Grand Rounds 24 May 2001.

Dr. M. Raymond

1) "Biological Variation: What is it and How can we use it?", Pathology Grand Rounds, 8 November 2001.

Dr. J. Rossiter

1) "BSE and Variant CJD", Pathology Grand Rounds, 8 March 2001.

Dr. C. Rowlands

1) "Urine Based Diagnosis of Bladder Cancer", Pathology Grand Rounds, 26 April 2001.

Dr. S. SenGupta

1) "Medical Staffing for Pathology Group Practices", Pathology Grand Rounds, 8 February 2001.

Dr. L. Shepherd

1) "The NCIC CTG Tumour/Data Bank: What's it all About", Pathology Grand Rounds, 4 October 2001.

Dr. S. Taylor

1) "Mermaids and Cyclops", Pathology Grand Rounds, 10 May 2001.

Dr. D. Zoutman

1) “Firstly do no Harm: The Status of Infection Prevention and Control Programs in Canadian Acute Care Hospitals”, Pathology Grand Rounds, 22 November 2001.

**INVITED LECTURES OUTSIDE OF KINGSTON
SENIOR STAFF
DEPARTMENT OF PATHOLOGY**

Dr. A.H. Boag

1) First Canadian Lung Cancer Research Workshop, University Health Network - Princess Margaret Hospital, Toronto, Ontario, June 2000

Dr. S. Cole

- 1) Department of Tumour Biochemistry, German Cancer Center, Heidelberg, Germany, March 12, 2001.
- 2) Department of Drug Metabolism and Pharmacokinetics, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgeway, CT, April 17, 2001.
- 3) Symposium, on "Biology of Cellular Invasiveness: Paths of Convergence in Pregnancy and Malignancy", Queen's University, Kingston, June 1, 2001.
- 4) 3rd FASEB Conference, on "Transport ATPases", Snowmass, CO, July 18, 2001.
- 5) Symposium, on "Childhood Cancer: From Mechanisms to Therapeutics", Children's Cancer Institute Australia, Sydney, Australia, October 8, 2001 (*Keynote speaker*).
- 6) 33rd Meeting of the International Society of Paediatric Oncology (SIOP), Brisbane, Australia, October 11, 2001 (*Keynote speaker*).
- 7) BC Cancer Agency, Vancouver, BC, November 19, 2001.
- 8) Dept. Microbiology & Immunology, Dalhousie University, Halifax, NS, November 21, 2001.
- 9) Oncology Rounds, Cancer Care Program, Nova Scotia Hospital, Halifax, NS, November 22, 2001.
- 10) Oncology Grand Rounds, Moffitt Cancer Center, Tampa, FL, November 30, 2001.

Dr. C. Collier

- 1) "Traipsing Through Troponin", Lennox & Addington Hospital, October 25, 2001.
- 2) "Quality Assurance of POCT", OSCC/QMPLS, Toronto, Ontario, November 7, 2001.

Dr. R. Deeley

- 1) 3rd FEBS Advanced Lecture Course in ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease, Gosau, Austria, March 3-10, 2001 (plenary speaker).
- 2) **Department of Oncology, London Regional Cancer Centre, Grand Rounds, January 2001.**

Dr. D. Dexter

- 1) International Conference for Coroners and Pathologists, Italy, "A Natural Death in a 48 Year Old", October 6-15, 2001.

Dr. B. Elliott

- 1) Canadian Breast Cancer Research Initiative Second Scientific Conference: Reasons for Hope 2001, "A Novel cSRC Tyrosine Kinase/Stat3 pathway in the Activation of Scatter Factor/HGF Expression in Mammary Carcinoma Cells", Quebec City, May 3-5, 2001.

Dr. K. Harrison

- 1) Clinical Applications of FISH, Michener Institute, April 17, 2001.

Dr. T. Karnauchow

- 1) Second Annual Eastern Ontario Regional Infectious Diseases and Medical Microbiology Conference, "Trends in Antibiotic Resistance", Mont Tremblant, PQ, October 13, 2001.
- 2) Infectious Diseases Rounds, Ottawa Hospital, "Slow Virus Infections: Measles and the CNS", October 2001.

Dr. R. Kisilevsky

- 1) Keystone Symposia, Neuronal and Vascular Stress: A New Window on Alzheimer's Disease, "Of Starch and Silk: In-vivo Amyloid Formation and Strategies for its Prevention", January 2001.
- 2) Department of Pathology, Baylor Medical College, Houston, Texas, 1) "The Biochemistry of In-vivo Amyloid Formation and Strategies for its Prevention"; 2) "Cholesterol Metabolism During Acute Inflammation, A Peek Through an Amyloid Window", January 2001.
- 3) Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden, "The Biochemistry of Amyloid Formation: An Analysis of an In Vivo Murine Model", April 2001.
- 4) IX International Symposium on Amyloidosis, Keynote Address, "AA amyloidogenesis: a progress report and possible future directions", Budapest, Hungary, July 2001.
- 5) Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala, Sweden, "Amyloid Formation: Examination of an Experimental Model, the Role of Heparan Sulphate and Strategies for its Prevention", September 2001.
- 6) The Biomedical Center, University of Uppsala, Uppsala, Sweden, "Exporting Cholesterol from Macrophages: A Peek Through an Amyloid Window", October 2001.

Dr. D. Lillicrap

- 1) 1st Meeting of the European Study Group on von Willebrand Disease. University of Sheffield, UK.
"A Canadian study of the molecular genetic basis of type 1 von Willebrand disease", January 2001.
- 2) Blood Borne Pathogens Division, Laboratory Centre for Disease Control, Health Canada, Ottawa, "A National Program for Hemophilia Genotyping", February 12, 2001.
- 3) Hemophilia Fair, Hemophilia Ontario – Hemophilia-Reconnecting our Community Retreat and Annual General Meeting. Kitchener, ON, "von Willebrand Disease – Diagnosis and Treatment", March 31, 2001.
- 4) The National Hemophilia Foundation 2001 Workshop on Gene Therapies for Hemophilia Salk Institute for Biological Studies, LaJolla, California, "Preclinical studies of hemophilia gene therapy in mice and dogs", April 19-21, 2001.
- 5) Canadian Society for Transfusion Medicine London, ON, "Current and Future Management of von Willebrand Disease", May 13, 2001.
- 6) IV International Workshop on Immune Tolerance in Haemophilia. Bonn, Germany, "Genotypes in hemophilia B inhibitor patients", August 31, 2001.
- 7) IV International Workshop on Immune Tolerance in Haemophilia. Bonn, Germany, "Immunologic sequences of adenovirus-mediated hemophilia gene therapy", September 1, 2001.
- 8) European Pediatric Hemophilia Group. Barcelona, Spain, "Hemophilia Gene Therapy: Current status and future prospects", September 22, 2001.
- 9) Heart and Stroke Foundation of Ontario, 50th Anniversary Meeting. Toronto, ON, "von Willebrand Factor as a Risk factor for arterial thrombosis", October 13, 2001.
- 10) National Hemophilia Foundation Symposium. Nashville, TN, "Why do Hemophiliacs bleed? - the impact of gene therapy", November 14, 2001.
- 11) Meet the Expert Session, American Society of Hematology Annual Meeting, Orlando, Florida, "Hemophilia Gene Therapy", December 9, 2001.

Dr. S. Ludwin

- 1) "MS Pathology: Lessons from Animal Models", Multiple Sclerosis Symposium "A Bench to Bedside Approach",

Division of Neurology, Hospital for Sick Children, Toronto Ontario, January, 2001.

2) MS Symposium, Targetting MS: Time Matters, Bermuda, "Pathology of Multiple Sclerosis", February 2001.

3) MS Preceptorship, Calgary Alberta, "Pathology of MS", March 2001.

4) Multiple Sclerosis: Current Status and Strategies for the Future Workshop, Washington, DC, April 2001.

5) Multiple Sclerosis 2001: A New Era in Research and Therapeutics Symposium, New Jersey Medical School,

"Issues in the Pathology of MS: Clinical and Experimental Studies", May 2001.

6) Invited discussant: Myelin Project Annual Meeting, Paris, France, September 2001.

7) University of Turin, Institute of Neurology, "The Pathology of Multiple Sclerosis Clinical and Experimental Studies, October 2001.

8) Sero Symposium on MS, Montreal, "Pathology of Multiple Sclerosis", November 2001.

9) University of Ottawa course on MS for Italian Neurologists, "Pathology of Multiple Sclerosis, December 2001.

Dr. D. Maurice

1) 4th Congress Of The European Society For Sexual And Impotence Research (ESSIR), **Plenary lecturer** "Mechanisms by which PDE inhibitors regulate vascular tone", Rome, Italy, September 29th, 2001. Other two lecturers a) Dr. Robert Furchgott; b) Dr. Clinton Webb

2) **Distinguished scientist seminar series.** "Cyclic Nucleotide Phosphodiesterases as Therapeutic Agents to Reduce Vascular Complications Associated with Angioplasty". University of South Alabama, Mobile, Alabama, U.S.A. Host: Dr. Samuel J. Strada, Ph.D, Senior Associate Dean, University of South Alabama, College of Medicine, Mobile, Alabama.

3) **Vascular Seminar Series.** "Cyclic Nucleotide Phosphodiesterase Inhibition: More than Erections" Hope Heart Institute, Seattle, Washington, U.S.A. Host: Dr. E. Helene Sage, Director, Vascular Biology, Hope Heart Institute, Seattle Washington, U.S.A.

Dr. M. Raymond

1) OSCC Annual Lectureship Award: "Biological Variation: What is it and How can we use it?", Toronto, ON, November 2001.

Dr. S. SenGupta

1) Pathology Examination of Breast Specimens. Ontario Breast Assessment Collaborative Group, Toronto, ON.

2) Medical Staffing for Pathology Group Practices. OAP 64th Annual Meeting, Alliston, ON.

Dr. L. Tomalty

1) 8th Undergraduate Microbiology Education Conference in Orlands, "Using ASM Resources in Preparing Power Point Presentations".

2) Ontario Medical Education Network Video Conference, "Promoting Active Learning with Technology".

Dr. D. Zoutman

1) 2 Mar 01, Community and Hospital Infection Control Association of Canada, Central Ontario Chapter,

Peterborough: Invited Speaker: Prevention and Management of Nosocomial Blood Borne Pathogens

2) 3 Oct 01, Hastings & Prince Edward County Health Unit, Belleville, Invited Speaker "Antibiotic Resistant Pathogens"

3) 20 Sep 01, ExtendaCare Inc, Kingston, Invited Speaker: "Urinary Tract Infections in Long Term Care"

4) 2 Aug 01, Rideaucrest Home, Kingston, Invited Speaker: "Management of Urinary Tract Infections"

**FULL PAPERS PUBLISHED
AND IN PRESS
2001**

FULL PAPERS PUBLISHED AND IN PRESS

A.H. Boag, L.A. Kennedy, M.J. Miller, B.Sc. Computerized Three-Dimensional Microscopic Image Reconstruction of Prostatic Adenocarcinoma, *Arch. Pathol. Lab. Med.* 125(4):562-566 (2001)

J.C. Nickel, L.D. True, J.N. Krieger, R.E. Berger, **A.H. Boag**, **I.D. Young**, and participating members of the North American Chronic Prostatitis Collaborative Research Network and the International Prostatitis Collaborative Network. Consensus Development of a Histopathological Classification System for Chronic Prostatic Inflammation, *Br. J. Urol.* 88:797-805 (2001)

D.T. Beiko, **A.H. Boag**, J.C. Nickel, J.R. Srigley. Benign Mixed Stromal Tumour of the Kidney of Possible Mullerian Origin. *J. Urol.* 166:1381-1382 (2001)

B. Elliott, W. Hung, **A.H. Boag** and A. Tuck. The Role of Hepatocyte Growth Factor/Scatter Factor in epithelial-mesenchymal transition and breast cancer. *Can. J. Physiol. Pharmacol.* (in press)

Y.M. Qian, W.C. Song, H.R. Cui, **S.P.C. Cole** and **R.G. Deeley**. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. *J. Biol. Chem.* 276: 6404-6411 (2001).

M.F. Rosenberg, Q. Mao, A. Holzenburg, R.C. Ford, **R.G. Deeley** and **S.P.C. Cole**. The structure of the multidrug resistance protein 1 (MRP1/ABCC1): crystallization and single-particle analysis. *J. Biol. Chem.* 276: 16076-16082 (2001).

D. Zhang, **S.P.C. Cole** and **R.G. Deeley**. Identification of an amino acid residue in Multidrug Resistance Protein (MRP)1 critical for conferring resistance to anthracyclines. *J. Biol. Chem.* 276: 13231-13239 (2001).

E.M. Leslie, Q. Mao, C.J. Oleschuk, **R.G. Deeley** and **S.P.C. Cole**. Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. *Molec. Pharmacol.* 59: 1171-1180 (2001).

K. Ito, S.L. Olsen, W. Qiu, **R.G. Deeley** and **S.P.C. Cole**. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. *J. Biol. Chem.* 276: 15616-15624 (2001).

L.C. Young, B.G. Campling, **S.P.C. Cole**, **R.G. Deeley** and J.H. Gerlach. Multidrug resistance proteins MRP3, MRP1 and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. *Clin. Cancer Res.* 7: 1798-1804 (2001).

R. Zimigibl, D. Schulze, S. Mirski, **S.P.C. Cole** and **P. Greer**. Subcellular localization analysis of the closely related Fps/Fes and Fer protein-tyrosine kinases suggests a distinct role for Fps/Fes in vesicular trafficking. *Exp. Cell Res.* 266: 87-94 (2001).

E.M. Leslie, **R.G. Deeley** and **S.P.C. Cole**. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. *Toxicology* 167: 3-23 (2001). (*invited peer-reviewed*).

E.M. Leslie, K. Ito, P. Upadyaya, S.S. Hecht, **R.G. Deeley** and **S.P.C. Cole**. Transport of the β -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1/ABCC1): Requirement for glutathione or a non-sulfur-containing analog. *J. Biol. Chem.* 276: 27846-27854 (2001).

E.U. Kurz, **S.P.C. Cole** and **R.G. Deeley**. Identification of DNA-protein interactions in the 5' flanking and 5' untranslated regions of the human multidrug resistance protein (MRP1) gene: Evaluation of a putative antioxidant response element/AP-1 binding site. *Biochem. Biophys. Res. Commun.* 285: 981-990 (2001).

D. Zhang, **S.P.C. Cole** and **R.G. Deeley**. Identification of a non-conserved amino acid residue in Multidrug Resistance Protein (MRP) 1 important for determining substrate specificity: evidence for functional interaction between transmembrane helices 14 and 17. *J. Biol. Chem.* 276: 34966-34974 (2001).

K. Ito*, C.J. Oleschuk*, C. Westlake, M.Z. Vasa, **R.G. Deeley** and **S.P.C. Cole**. Mutation of Trp¹²⁵⁴ in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. *J. Biol. Chem.* 276: 38108-38114 (2001). (*these two authors contributed equally to this work).

Y.M. Qian, W. Qiu, M. Gao, C.J. Westlake, **S.P.C. Cole** and **R.G. Deeley**. Characterization of binding of leukotriene C₄ by human multidrug resistance protein 1: evidence of differential interactions with NH₂- and COOH-proximal halves of the protein. *J. Biol. Chem.* 276: 38636-38644 (2001).

S. Conrad, H-M. Kauffmann, K-i. Ito, **R. Deeley**, **S.P.C. Cole** and D. Schrenk. Identification of human multidrug resistance protein 1 (*MRP1*) mutations and characterization of a G671V substitution. *J. Hum. Genet.* 46: 656-663 (2001).

R.L. Houlden, **C.P. Collier**, P.J. Frid, S.L. John, H. Pross. Problems Identified by Tutors in a Hybrid Problem-based Learning Curriculum. *Academic Medicine*, Vol. 76, No. 1, January 2001.

C.P. Collier, A.T. Crowe, R.A. Stinson, S.Y. Chu, R.L. Houlden. The Continuing Professional Development Program of the Canadian Society of Clinical Chemists and Canadian Association of Clinical Biochemists. *Clin Biochem* 34:91-96 (2001).

R.L. Houlden, **C.P. Collier**, D. Yen. Cooking from Scratch: Teaching Residents Life Long Learning Skills. *Annals RCPSC*, Vol. 34, number 7, October 2001

L. Hookey, **D. Dexter** and D.H. Lee. The Use and Interpretation of Quantitative Terminology in reporting of Red Blood Cell Morphology. *Laboratory Haematology* 7:85-88, 2001.

W. Hung and **B.E. Elliott**. Cooperative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells. *J. Biol. Chem.* 276:12395-403, 2001.

A.A. Krzemien, D.A. Van Vugt, **W.A. Fletcher** and R.L. Reid. Effectiveness of Photodynamic Ablation for Destruction of Endometrial Explants in a Rat Endometriosis Model. In Press.

R. Zirngibl, Y. Senis and **P.A. Greer**. Enhanced endotoxin-sensitivity in Fps/Fes-null mice with minimal defects in hematopoietic homeostasis. (In Press)

N. Dourdin, A.K. Bhatt, **P.A. Greer**, J.S.C. Arthur, J.S. Elce and A. Huttenlocher. Reduced cell migration and disruption of the actin cytoskeleton in calpain-deficient embryonic fibroblasts. *J. Biol. Chem.* 276: 48382-48388, 2001.

P. Keller, J.L. Payne, G. Tremml, **P.A. Greer**, M. Gaboli, P.P. Pandolfi and M. Bessler. FES-Cre targets PIGA inactivation to hematopoietic stem cells in the bone marrow. *J. Exp. Med.* 194: (5) 581-589, 2001

D.E. Bovenkamp and **P.A. Greer**. Degenerate PCR-based cloning method for Eph receptors and analysis of their expression in the developing murine CNS and vasculature. *DNA and Cell Biology* 20:203-213, 2001.

A.W.B. Craig, R. Zirngibl, K. Williams, K., L.A. Cole and P.A. Greer. Mice devoid of Fer protein-tyrosine kinase activity are viable and fertile, but display reduced cortactin phosphorylation. *Molecular and Cellular Biology* 21:603-613, 2001.

C. Forster-Gibson, J. Davies, J. MacKenzie and K. Harrison. Cryptic duplication of 21q in an individual with a clinical diagnosis of Down Syndrome. *Clinical Genetics* 59(6): 438-43, 2001.

M. Schurter, **D.P. LeBrun**, and **K. Harrison**. Improved technique for fluorescence in situ hybridization analysis of isolated nuclei from archival, B5- or formalin-fixed, paraffin-embedded tissue. Submitted to *Molecular Pathology*, (In Press).

R.L. Barclay, S.J. Vanner and **D.J. Hurlbut**. Major hemorrhage from an unusual gastric tumor. *Gastrointestinal Endoscopy* 53(6):628, 2001.

R.L. Barclay, J.B. Simon, S.J. Vanner, D.J. Hurlbut and J.F. Jeffrey. Case Report: Rectal passage of intestinal endometriosis. *Digestive Diseases and Sciences* 46(9):1963-67, 2001.

S. Ely, R. Bonatesta, J.B. Ancsin, M. Kindy and **R. Kisilevsky**. The In-vitro Influence of Serum Amyloid A isoforms on Enzymes that Regulate the Balance Between Esterified and Un-esterified Cholesterol. *Amyloid* 8: 169-181, 2001.

D.S. Yang, L.C. Serpell, C.M. Yip, J. McLaurin, M.A. Chrishti, P. Horne, **R. Kisilevsky**, D. Westaway and P.E. Fraser. Assembly of Alzheimer's Amyloid- β Fibrils and Approaches for Therapeutic Intervention
Amyloid 8: Suppl 1, 10-19, 2001.

S. Inoue and Kisilevsky. "β-amyloid fibrils of Alzheimer's disease: pathologically altered basement membrane-associated microfibrils?" *Ital.J.Anat.Embryol.* 106 (Suppl.1): 93-102, 2001.

A.Barkin, W.A. Szarek and **R. Kisilevsky**. Synthesis and Biological Evaluation of a Radiolabeled Analog of Methyl 2-Acetamido-2,4-dideoxy- β -D-xylo-hexopyranoside Directed Towards Influencing Cellular Glycosaminoglycan Biosynthesis. *Carbohydrate Res.*337: 37-44 (In Press).

K. Ohashi, **R. Kisilevsky** and M. Yanagishita. Affinity Binding of Heparin with β 2-microglobulin, *Nephron.* 90: 158-168. (In Press).

R. Kisilevsky and S.P. Tam. Serum Amyloid A, Cholesterol Metabolism, and Cardiovascular disease *Pediatr. Pathol. Mol. Med.* (In Press).

M.N. Rutherford, G.R.L. Bayly, B.P. Matthews, T. Okuda, W.M.N. Dinjens, H. Kondoh and D.P. LeBrun. The leukemogenic transcription factor E2A-Pbx1 induces expression of the putative N-myc and p53 target gene *NDGRI* in bAfl3 cells. *Leukemia* 15(3):362, 2001.

M. Schurter, **D.P. LeBrun** and **K.J. Harrison.** Improved technique for fluorescence in situ hybridization analysis of isolated nuclei from archival, B5- or formalin-fixed, paraffin-embedded tissue. *Hum Pathol*, (In Press).

A.M. Gallo-Penn, P.S. Shirley, J.L. Andrews, S. Tinlin, S. Webster, S. Cameron, C. Notley, C. Hough, **D. Lillicrap**, M. Kaleko and S. Connelly, S. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. *Blood*, 97:107-113, 2001.

T.M. Johnson, S. El-Defrawy, W.G. Hodge, B.C. Leonard, P.J. Kertes, **S.A.M. Taylor**, and **D. Lillicrap.** Prevalence of Factor V Leiden and activated protein C resistance in central retinal vein occlusion. *Retina* 21 (2):161-6, 2001.

D. Lillicrap. The genetics of venous and arterial thromboembolism. *Current Atherosclerosis Reports* 3(3):209-15, 2001.

R. DiBitondo, C. Cameron, M. Daly, S. Croft, R. Steeds, K. Channer, N. Samani, **D. Lillicrap** and P. Winship, P. The -1185 A/G and 1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction. *Br. J. Haematol.* 115:701-706, 2001.

Y. Xie, H. Zheng, J. Leggo, M-F. Scully and **D. Lillicrap.** A founder factor VIII mutation, valine 2016 to alanine, in a population with an extraordinarily high prevalence of mild hemophilia A. *Thrombosis and Hemostasis*, 87:178-179 (In Press).

D. Lillicrap, M.-C. Poon, I. Walker, F. Xie, B.A. Schwartz, B.A. and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the Factor VIII/von Willebrand Factor concentrate, Haemate-P/Humate-P, administered in Ristocetin Cofactor Unit doses to patients with von Willebrand disease. *Thrombosis and Haemostasis*, 87:224-230 (In Press).

M-C. Poon, **D. Lillicrap**, C. Hensman, R. Card, M-F. Skully and members of the Association of Hemophilia Clinic Directors of Canada. Recombinant factor IX recovery and inhibitor safety: A canadian post-licensure surveillance study. *Thrombosis and Haemostasis*, 87:431-435 (In Press).

C. Hough, S. Kamisue, C. Cameron, C. Notley, S. Tinlin, A.R. Giles and **D. Lillicrap.** Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. *Thrombosis and Haemostasis* (In Press).

B. Brown and **D. Lillicrap.** Dangerous liaisons: The role of "danger" signals in the immune response to gene therapy. *Blood* (In Press).

L.W. Whitney, **S. K. Ludwin**, H.F. McFarland and W.E. Biddison. Microarray Analysis of Gene Expression in Multiple Sclerosis and EAE Identifies 5-Lipoxygenase as a Component of Inflammatory Lesions. *Journal of Neuroimmunology* 121 (2001) 40-48.

M.A. Moscarello, B. Mak, D.D. Wood and S.K. Ludwin. Paclitaxel attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination. Multiple Sclerosis (2001) (In Press)

S.L. Jimmo, S. Netherton, D. Palmer, D.G. Tilley, H.A. Dunkerley, D.R. Raymond, J.C. Russell, E.H. Sage, R.B. Vernon and **D.H. Maurice**. An increased role for phosphodiesterase 3-mediated cAMP hydrolysis in obese JCR:LA-cp rat aortic vascular smooth muscle cells: Association with a hypermigratory phenotype. *Diabetes* (In Press)

H.A. Dunkerley, D.G. Tilley, D. Palmer, S.J. Jimmo and **D.H. Maurice**. Reduced phosphodiesterase 3 activity and phosphodiesterase 3A levels in synthetic vascular smooth muscle cells: Implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. *Mol. Pharmacol. Accelerated Communication* (In Press).

J.P. Rossiter, L.L. Anderson, F. Yang and G.M. Cole. Aspase-3 Activation and Caspase-like Proteolytic Activity in Human Perinatal Hypoxic-Ischemic Brain Injury. *Acta Neuropathologica* 103: 66-73 (In Press).

C.G. Coolcott, K.J. Aronson, W.M. Hanna, **S.K. SenGupta**, D.R. McCready, E.E. Sterns and A.B. Miller. Organochlorines and Breast Cancer Risk by Receptor Status, Tumour size and Grade. *Cancer Causes and Control*. 12:395-404, 2001.

K. Pritchard, A.H.G. Paterson, S. Fine, N. Paul, B. Zee, **L. Shepherd**, H. Abu-Zahra, J. Ragaz M. Knowling, M. Levine, S. Verma, D. Perrault, D. Walde, V. Bramwell, M. Poljicak, N. Boyd, D. Warr, B. Norris, D. Bowman, G. Armitage, H. Weizel and R. Buckman. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. *Classic Papers and Current Comments* 5(4):658-68, 2001.

D.J. Sargent, R.M. Goldberg, S.D. Jacobson, J.S. MacDonald, R. Labianca, D.G. Haller, **L.E. Shepherd**, J.F. Seitz and G. Francini. A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. *NEJM*, Vol. 345:1091-1097 (October 11, 2001)

V.A. Morrison, K.R. Rai, B.L. Peterson, J.E. Kolitz, L. Elias, F.R. Appelbaum, J.D. Hines, **L. Shepherd**, R.E. Martell, R.A. Larson and C.A. Schiffer. Impact of Therapy with Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections In Patients with Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. *J of Clinical Oncology*, Vol. 19, No. 16 (August 15), 2001: pp 3611-3621.

D. Baeko, **L. Tomalty** and W. Woebesser. The role of Cryptococcal Latex Antigen Tests. *Clinical Microbiology Newsletter*, 23:8, 2001.

J. Cataudella, **I.D. Young** and E. Iliescu. Epstein-Barr Virus - Associated Acute Interstitial Nephritis: Infection or Immunologic Phenomenon? *Nephron* (In Press)

D.A. Peters, J.F. Watkins and **I.D. Young**. Lymphoepithelioma-like Carcinoma of the Skin. Canadian Journal of Plastic Surgery (In Press)

F. Wright, D.K. Heyland, J.W. Drover, S. McDonald and **D. Zoutman**. Antibiotic-coated central lines: Do they work in the critical care setting? Critical Care Medicine, 12(1): 21-28, 2001.

M. Hyland M et al and Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Nosocomial *Clostridium difficile* associated diarrhea (N-CDAD) in Canada: The results of the Canadian Nosocomial Infection Surveillance Program 1997 N CDAD prevalence surveillance project. Can. J. Infect. Dis., 12(2): 81-88, 2001.

Infection Prevention and Control Alliance (includes **D. Zoutman**). Development of a resource model for infection prevention and control programs in acute, long term, and home care settings. Can J Infect Control 16(2): 35-39, 2001.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Reuse of single-use medical devices in Canadian acute care healthcare facilities. Can Comm Dis Report 27(23): 193-199, 2001.

D. Zoutman, C. Fleming, Quality Management Program-Laboratory Services Microbiology Committee, and H. Richardson. Compliance with NCCLS Approved Standard M22-A2 for bacteriologic media quality assurance: a survey of 124 Ontario microbiology laboratories. Diagnostic Microbiology and Infectious Disease, 42: 29-34, 2001.

A.E. Simor AE et al and Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). The evolution of methicillin resistant *Staphylococcus aureus* in Canadian hospitals: The results of five years of national surveillance. Can. Med. Assoc. J. 165: 21-26, 2001.

M.A. Miller et. al. and Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Morbidity, mortality, and health-care burden of nosocomial *Clostridium difficile*-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2001 (In press).

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Central venous catheter-associated blood stream infections occurring in Canadian intensive care units: A six month prospective study. Infection Control and Hospital Epidemiology. 2001 (In Press).

A. Stratford, **D. Zoutman** and J. Davidson. The use of lidocaine as an antimicrobial agent. Plastic and Reconstruct Surg, 2001 (In press).

BOOK CHAPTERS

- S.P.C. Cole** and **R.G. Deeley**. Multidrug Resistance II – MRP and Related Proteins. In: Encyclopedia of Cancer – Second Edition (ed. J.R. Bertino). Academic Press, San Diego, CA. In Press.
- R.G. Deeley** and **S.P.C. Cole**. Multidrug Resistance Protein 1 (ABCC1). In: ABC Proteins: From Bacteria to Man. (eds. I.B. Holland, K. Kuchler, C.F. Higgins and **S.P.C. Cole**). ISBN: 0123525519. In Press.
- R. Zirngibl and **P. Greer**. Analysis of protein kinase subcellular localization by visualization of GFP fusion proteins. *Methods in Molecular Biology* 124:195-208, 2001.
- J.B. Ancsin and **R. Kisilevsky**. 'Serum Amyloid A Peptide Interactions with Glycosaminoglycan: Evaluation by Affinity Chromatography', Chapt. 44. In: *Methods in Molecular Biology*, Vol 171: Proteoglycan Protocols, Ed., Iozzo R.V. The Humana Press Inc., Totowa, NJ, 2001, pp 449-456
- R. Kisilevsky**. "Prospects for Treatment" in *Conformational Diseases - A Compendium: Based on the First International Workshop on Conformational Diseases - 1998 Ein Boqueq, Israel November 8 - 12, 1998*. Eds. B. Solomon, A. Taraboulos, and E. Katchalski-Katzir, 2001, pp 262-265.
- R. Kisilevsky** and W.A. Szarek. Novel Glycosaminoglycan Precursors as Anti-amyloid Agents, in *Drug Discovery and Development for Alzheimer's Disease 2000*, Eds. H. M. Fillit and A.W. O'Connell Springer Publishing Company, New York, pp 98-105, 2002
- R. Kisilevsky** and W.A. Szarek. Novel Glycosaminoglycan Precursors as Anti-amyloid Agents: Part II
Institute For the Study of Aging: Second Annual Investigator's Meeting Springer Publishing Company (In Press).
- S.K. Ludwin**. The Neuropathology of Multiple Sclerosis. In: *Magnetic Resonance Imaging Clinics of North America* (in press), edited by Dr. Joseph Frank; published by W.B. Saunders.
- G.M. Petari, **D.H. Maurice**, S.A. Waldman and B.M. Bennett. Cyclic nucleotides and protein phosphorylation in vascular smooth muscle relaxation. *In Physiology and Pathophysiology of the Heart*, 4th Edition. Edited by N. Sperelakis, Y. Kurachi, A. Terzic, M.V. Cohen, Academic Publishers, Boston, 2001.
- S. Gluck, M. Crump, D. Stewart, A. Arnold, S. Couban, P. Kirkbride, E. Levine, S. O'Reilly, K. Pritchard, A. Smith, D. Tu, J. Dancey, S. Marlin and **L. Shepherd**. Summary of Current Studies in Breast Cancer using High-dose Chemotherapy and Autologous blood cell transplantation, including NCIC CTG MA. 16. In: K.A. Dicke, A. Keating eds. *Autologous Blood and Marrow Transplantation X*. Charlottesville, Virginia: Carden Jennings Publishings, p. 106-112, 2001.

L. Tomalty, G. Felisle. Hyperclinic 2: Interactive Case Studies in Microbiology. Multimedia CD ROM. McGraw Hill Publishers, 2001.

G. Delisle and **L. Tomalty**. Microbes in Motion 3. Multimedia CD ROM. McGraw Hill Publishers, 2001.

ABSTRACTS 2001

ABSTRACTS

- R.G. Deeley** and **S.P.C. Cole**. Transport by human and murine MRP1 structural determinants of substrate specificity and functional differences between nucleotide binding domains. 3rd FEBS Advanced Lecture Course ATP-Binding Cassette (ABC) Proteins From Multidrug Resistance to Genetic Disease. Gosau, Austria, March 3-10, 2001. (*invited*)
- E.M. Leslie*, K. Ito, P. Upadhyaya, S.S. Hecht, **R.G. Deeley** and **S.P.C. Cole**. Active transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen NNAL by MRP1/ABCC1: Requirement for GSH or a non-sulfur-containing analog. 3rd FEBS Advanced Lecture Course ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease. Gosau, Austria, March 3-10, 2001. (**recipient of a NCIC Student Travel Award; recipient of a FEBS conference bursary; recipient of a a Gosau Young Investigators Award*)
- K. Ito, W. Qiu, **R.G. Deeley** and **S.P.C. Cole**. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport activity. 3rd FEBS Advanced Lecture Course ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease. Gosau, Austria, March 3-10, 2001.
- C. Westlake, M. Gao, **S.P.C. Cole** and **R.G. Deeley**. Structure and function analysis of the MRP1 cytoplasmic loop 3rd FEBS Advanced Lecture Course ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease. Gosau, Austria, March 3-10, 2001.
- D. Zhang, **S.P.C. Cole** and **R.G. Deeley**. Identification of an amino acid residue in Multidrug Resistance Protein (MRP1) critical for conferring resistance to anthracyclines. 3rd FEBS Advanced Lecture Course ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease. Gosau, Austria, March 3-10, 2001.
- P.W. Causey, M.C. Baird, **S. P.C. Cole** and K. Sparks. In search of titanium-based anticancer agents. 84th Canadian Society for Chemistry Conference Exhibition. Montréal, PQ, May 26-30, 2001.
- C.J. Oleschuk, K. Ito, C. Westlake, M. Vasa, **R.G. Deeley** and **S.P.C. Cole**. Modulation of substrate specificity by mutation of Trp¹²⁵⁴ in the apical membrane transporter MRP2. 4th Annual Meeting for Basic and Clinical Research Trainees. Faculty of Health Sciences, Queen's University, May 31, 2001.

E.M. Leslie, **R.G. Deeley** and **S.P.C. Cole**. Transport of the β -*O*-glucuronide conjugate of the carcinogen NNAL by the multidrug resistance protein 1 (MRP1/ABCC1). 4th Annual Meeting for Basic and Clinical Research Trainees. Faculty of Health Sciences, Queen's University, May 31, 2001.

D.-W. Zhang, **S.P.C. Cole** and **R.G. Deeley**. Identification of amino acid residues in multidrug resistance protein (MRP)1 important for drug resistance and 17 β -estradiol 17-(β -D-glucuronide) transport: evidence for functional interaction between amino acids in transmembrane helices (TM) 14 and 17. 4th Annual Meeting for Basic and Clinical Research Trainees. Faculty of Health Sciences, Queen's University, May 31, 2001.

M. Muredda, R. Burch-Wright, **S.P.C. Cole** and **R. Deeley**. Cloning and Analysis of the Murine Multidrug Resistance Protein (mrpl) Promoter. 4th Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University, May 31, 2001.

C. Westlake, Y. Qian, M. Gao, **S.P.C. Cole** and **R.G. Deeley**. Structure and function analysis of MRP1 cytoplasmic Loop 3. 4th Annual Meeting for Basic and Clinical Research Trainees. Faculty of Health Sciences, Queen's University, May 31, 2001.

S.P.C. Cole and **R.G. Deeley**. MRP1: An ABC transporter of drugs and toxins. 3rd FASEB Conference on [Transport ATPases], Snowmass, CO, July 18, 2001. (invited)

A. Ilhan, O. Tomris, A. Hakan, S. Yenisoy, S. Burhan and **S.P.C. Cole**. Multidrug resistance-associated protein (MRP1) gene transfection confers resistance to doxorubicin, etoposide and vincristine, but not to paclitaxel and cisplatin in kidney cells. Balcan J. Clin. Lab. VIII: pp-061. 9th Meeting of the Balkan Clinical Laboratory Federation, Ioannina, Greece, September 12-15, 2001.

S.P.C. Cole. ABC transporters and drug resistance. Symposium on [Children's Cancer: From Mechanisms to Therapeutics], Sydney, Australia, October 8, 2001 (*Keynote speaker*).

S.P.C. Cole. MRP-related ABC transporters defining their roles in drug sensitivity and resistance. 33rd Meeting of the International Society of Paediatric Oncology (SIOP), Brisbane, Australia, October 11, 2001 (*Keynote speaker*).

E.M. Leslie*, R.J. Bowers, **R.G. Deeley** and **S.P.C. Cole**. Structure activity studies of glutathione analogues that stimulate estrone 3-sulfate transport by the multidrug resistance protein, MRP1. STC Annual Symposium, Montréal, Quebec, December 6-7, 2001. (**recipient of an STC Travel Award*)

C.J. Oleschuk, K-i. Ito, C. Westlake, M. Vasa, **R.G. Deeley** and **S.P.C. Cole**. Modulation of substrate specificity by mutation of Trp¹²⁵⁴ in the apical membrane transporter MRP2. STC Annual Symposium, Montréal, Quebec, December 6-7, 2001.

M. Adachi, K-i. Nunoya, J. Sampath, D. Sun, G. Du, M. Leggas, C. Stewart, **S. P.C. Cole**, **R. Deeley** and J. Schuetz. The MRP4 gene transports cyclic nucleotides and is directly regulated by the PKA signaling pathway: implications for biological role. 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 6-10, 2002.

J.A. Simpson, R. Labugger, A. Ha, **C. Collier**, C.D. D'Arsigny, D. O'Donnell, S. Iscoe, J.E. Van Eyk. Serum levels of Skeletal Troponin I: A Marker of Respiratory Muscle Dysfunction? Am. J. Respir. Crit. Care Med. 163:A512, 2001.

D.A. Colantonio, W. Pickett, R.J. Brison, **C.P. Collier** and J.E. Van Eyk. Detection of Cardiac Troponin I early after onset of symptoms of Acute coronary Syndromes. AACCC/SCCC, July 2001

W. Hung and **B. Elliott**. Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. Signalling in Normal and Cancer Cells Meeting, Banff, Alberta, Canada, March 2-6, 2001.

B. Elliott, H. Qiao, E. Lin, D. Louvard and M. Arpin. Role of c-Src and the membrane cytoskeletal cross-linker Ezrin in formation of cell-cell contacts by mammary carcinoma cells. Signalling in Normal and Cancer Cells Meeting, Banff, Alberta, Canada, March 2-6, 2001.

W. Hung and **B. Elliott**. A novel c-SRC Tyrosine Kinase/Stat3 pathway in the activation of scatter factor/HGF expression in mammary carcinoma cells. Canadian Breast Cancer Research Initiative Second Scientific Conference: Reasons for Hope 2001. Quebec City, May 3-5, 2001.

W. Sangrar, R. Zirngibl, J. Mewburn, Y. Senis, C. Chapler, D. Lee and **P.A. Greer**. A murine transgenic line expressing a myristoylated form of Fps/Fes is characterized by disorganized hyper-vascular patterning and peripheral blood defects. American Society of Hematology. Orlando, Florida 2001.

Y.A. Senis, R.A. Zirngibl, W. Sangrar, N.T. Peterson, D. Lee and **P.A. Greer**. Fps and Fer are expressed in human and mouse platelets and become tyrosine phosphorylated following collagen and thrombin stimulation. American Society of Hematology. Orlando, Florida 2001.

A.W. Craig and **P.A. Greer**. Activation of Fer and Fps/Fes protein-tyrosine kinases upon aggregation of Fc γ RI on mouse bone marrow-derived mast cells. American Society of Hematology, Orlando, Florida 2001.

A.W. Craig, D.M. McCafferty, P. Kubes and **P.A. Greer**. Mice devoid of Fer protein-tyrosine kinase activity are viable and fertile, but display reduced cortactin phosphorylation and hyperinflammatory responses. Fifth Conference on Signalling in Normal and Cancer Cells, Banff, Alberta 2001.

*W. Sangrar, R.A. Zirngibl, K.A. Williams, W.J. K.A. Muller and **P.A. Greer**. Early mammary tumour development in polyomavirus-middle-T transgenic mice which harbour null or kinase-inactivated *fps* alleles. Fifth Conference on Signalling in Normal and Cancer Cells, Banff, Alberta 2001.

C. Forster-Gibson and **K. Harrison**. Cryptic Y Chromosome Rearrangement and 4 copies of 8RY Identified in an Adult with a Marker Chromosome using Molecular Cytogenetic Techniques. Abstract submitted to 14th International Chromosome Conference, Sept. 4-8, 2001, Wurzburg, Germany.

T. Karnachow, J.P. Rossiter, P. Rota and W.J. Bellini. Virologic and Histopatologic Findings in a case of Adult-Onset Subacute Sclerosing Panencephalitis (SSPE). Seventeenth Annual Clinical Virology Symposium of the Pan American Society for Clinical Virology, Clearwater Beach, Florida, May 2001.

S.P. Tam, A. Flexman, J. Hulme and **R. Kisilevsky**. The physiological role of serum amyloid A 2.1. IXth International Amyloid Symposium, Budapest, Hungary, July 15-21, 2001. Amyloid 8: Suppl 2, 21-22, 2001.

J.B. Ancsin and **R. Kisilevsky**. Investigation of the serum amyloid A binding site(s) on heparin/heparan sulfate. IXth International Amyloid Symposium, Budapest, Hungary, July 15-21, 2001. Amyloid 8: Suppl 2, 37, 2001.

J.B. Ancsin, E. Elimova and **R. Kisilevsky**. Serum Amyloid A has two heparin/heparan sulfate binding sites with different pH optima. IXth International Amyloid Symposium, Budapest, Hungary, July 15-21, 2001. Amyloid 8: Suppl 2, 40, 2001.

R. Kisilevsky, and J.B. Ancsin. Keynote Lecture. AA amyloidogenesis: a progress report and possible future Directions. IXth International Amyloid Symposium, Budapest, Hungary, July 15-21, 2001. Amyloid 8: Suppl 2, 35-36, 2001.

R. Kisilevsky and J.B. Ancsin. Proteoglycans in AA amyloidosis. AA amyloidogenesis: a progress report and possible future directions. IXth International Amyloid Symposium, Budapest, Hungary, July 15-21, 2001

L. O'Brien, K. Benford, H. Racz, D. Rapson and **D. Lillicrap**. Identification of a novel 2A von Willebrand disease candidate mutation, Leu740 Gln, in the A2 domain of von Willebrand factor. XVIII Congress of the International Society on Thrombosis and Haemostasis submitted for ISTH Paris July 6-12, 2001.

C. Hough, C. Cameron, S. Kamisue, C. Notley, **D. Lillicrap**. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A. XVIII Congress of the International Society on Thrombosis and Haemostasis submitted for ISTH Paris July 6-12, 2001.

C. Cameron, A. Keightley, E. Bwerber, C. Hough and **D. Lillicrap**. Evidence for allele-specific shear stress responsiveness of the von Willebrand factor regulatory sequence. XVIII Congress of the International Society on Thrombosis and Haemostasis Submitted for ISTH Paris July 6-12, 2001.

S.A. Taylor, S. M. Kinkley, B. Brown, A.T. Lyng, G.N. Schep and **D. Lillicrap**. Genetic analysis of a 22bp deletion of the Hfe gene. Submitted to the 10th International Congress of Human Genetics, May 2001.

C. Hough, C. Cameron, S. Kamisue, C. Notley and **D. Lillicrap**. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A. Thrombosis and Haemostasis, Abstract P248, Supplement July 2001.

C. Cameron, A. Keightley, E. Berber, C. Hough and **D. Lillicrap**. Evidence for allele-specific shear stress responsiveness of the von Willebrand factor regulatory sequence. Thrombosis and Haemostasis, Abstract OC892, Supplement July 2001.

T. Vanden Driessche, A. Van Damme, L. Naldini, **D. Lillicrap**, B. Vanzielegem, J.M. Saint Remy, D. Collen and M. Chuah. Lentiviral and retroviral vector-based gene therapy for hemophilia A in factor VIII-deficient mice. Thrombosis and Haemostasis, Abstract P1836, Supplement July 2001.

X-G. Xie, H. Zheng, D. MacGregor, J. Leggo, R. Bagnell, P. Green, B. Fernandez, D. Robb, M.F. Scully and **D. Lillicrap**. A founder factor VIII mutation, valine 2016 to alanine in a population with extraordinary high prevalence of mild hemophilia A. Thrombosis and Haemostasis, Abstract OC196, Supplement July 2001.

L. O'Brien, K. Benford, H. Racz, **D. Rapson** and **D. Lillicrap**. Identification of a novel 2A von Willebrand disease candidate mutation, Leu740/Gln, in the A2 domain of von Willebrand factor. Thrombosis and Haemostasis, Abstract CD3328, Supplement July 2001.

S.A. Taylor, S.M. Kinkley, B. Brown, A.T. Lyng, G.N. Schep and **D. Lillicrap**. Genetic analysis of a 22bp deletion of the Hfe gene. 10th International Congress of Human Genetics, May 2001.

S.K. Ludwin, J.M. Henry and H. McFarland. Vascular Proliferation and Angiogenesis in Multiple Sclerosis: Clinical and Pathogenetic Implications. J. Neuropath. Exptl. Neurol. 60:505, 2001.

H.A. Dunkerley and **D.H. Maurice**. Differential Cyclic Nucleotide Expression in Cultured and Intimal Vascular Smooth Muscle Cells. 41st American Society for Cell Biology Annual Meeting in Washington, DC, December 8-12, 2001.

D.G. Tilley and **D.H. Maurice**. *In vivo* regulation of Phosphodiesterase activity and expression. 41st American Society for Cell Biology Annual Meeting in Washington, DC, December 8-12, 2001.

S. Netherton, S.L. Jimmo and **D.H. Maurice**. Involvement of phosphodiesterase 3 in hyperproliferative phenotype of JCR:LA-cp rats. 41st American Society for Cell Biology Annual Meeting in Washington, DC, December 8-12, 2001.

D. Rapson, M. Silva, M. Gibson and L. Kerr. Comparison of Current Central Line Practices in Canadian Paediatric Oncology Centres. Poster presented at the POGO Meeting, November 9-10, 2001.

A. Rico-Lazarowski, H. Doobay, L. Dwyre, K. Klemp, T.L. Ortel and **D. Rapson**. Tekjidor L.Clinical Evaluation of a New ISI Thromboplastin Reagent Prepared from Cultured Human Lung Cells. Duke University Medical Center, Durham NC, USA; Kingston General Hospital, Kingston,

Ontario, Canada; and Biomerieux, Durham, NC, USA. Abstract, International Society of Thrombosis and Haemostasis Meeting, June 6-12, 2001, in Paris, France.

J.P. Rossiter & L.L. Anderson. Immunohistochemical detection of axonal injury in very short survival head injury cases. *Journal of Neuropathology & Experimental Neurology* 60(5) 558, Abstract 222, 2001.

J.P. Rossiter & D. Lee. Cerebellar liponeurocytoma: diagnostic case presentation. Canadian Association of Neuropathologists, 41st Annual Meeting, 2001.

T. Karnachow, J.P. Rossiter, P. Rota, W.J. Bellini, M. Melanson. An unusual case of adult-onset subacute sclerosing panencephalitis (SSPE). 84th Canadian Society for Chemistry Conference & Exhibition, June 2001

A.P. Lyon, K.A. Jones, M.G. Buhendwa, A.J. Hanson, **J.P. Rossiter** & D.F. Weaver. Anti-epileptogenic activity of beta-amino acids. 84th Canadian Society for Chemistry Conference and Exhibition, Montreal, June 2001.

T.M. Childs and **C.G. Rowlands.** Long Term Outcome for Women with Atypical Squamous Cells of Undetermined Significance. Presented at CAP 2001.

C.G. Woocott, K.J. Aronson, W.M. Hanna, **S.K. SenGupta**, D.R. McCready, E.E. Sterns and A.B. Miller. Breast Cancer Risk by Tumour Characteristics. Congress of Epidemiology 2001 (Toronto).

L. Shepherd, F. O'Malley, P. Watson, B. Chir, M. Levine, I. Andrulus, V. Bramwell, B. Gubbins, K. Pritchard. The Role of NEU/ERB B-2 as a Predictive Factor for Differential Response to Adjuvant Chemotherapy and Tamoxifen: National Cancer Institute of Canada Clinical Trial Groups (NCIC CTG) Experience in Retrospective Paraffin Embedded Tissue Collection. Presented at the Reasons for Hope. CBCRI, May 2001, Quebec City

S. Ackland, M. Moore, M. Jones, D. Tu, R.J. Simes, J. Yuen, A. Sargeant, H. Dhillon, R. Goldberg, E. Abdi and **L. Shepherd.** A meta-analysis of two randomized trials of early chemotherapy in asymptomatic metastatic colorectal cancer. *Proc. Am. Soc. Clin. Oncol.* 20:132a, 2001

M. Crump, S. Gluck, D. Stewart, M. Levine, K. Pritchard, P. Kirkbride, J. Dancey, S. O'Reilly, T. Shore, S. Couban, C. Girouard, H. Abu-Zahra, D. Tu, S. Marlin, **L. Shepherd.** A randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study. *Proc. Am. Soc. Clin. Oncol.* 20:21a, 2001.

M. Crump, D. Tu, **L. Shepherd**, R. Levine, V. Bramwell and K. Pritchard. Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer. Presented at the 24th San Antonio Breast Cancer Symposium, 2001.

S. Gluck, M. Crump, D. Stewart, M. Levine, K. Pritchard, P. Kirkbride, J. Dancey, S. O'Reilly, T. Shore, S. Couban, C. Girouard, H. Abuzara, D. Tu, S. Marlin and **L. Shepherd.** A randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard chemotherapy in women with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group Study. *Eur. J. Can.* 37(6):S285, 2001.

Y. Madarnas, S. Fine, C. Sawka, **L. Shepherd**, I. Tannock, D. Tu and M. Levine. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: Results from a National Cancer Institute of Canada randomized controlled trial. Presented at the Annual Meeting of the North American Association for the Study of Obesity 9:151S, 2001.

M. O'Connell, J. Skillings, H. Windschitl, **L. Shepherd**, D. Sargent, J. Krook, M. Tria Tirona, R. Morton, K. Rowland, J. Rubin and J. Kugler. Phase III trial of high dose levamisole + 5-fluorouracil + leucovorin as adjuvant treatment for high risk colon cancer: an NCCTG/NCIC study. Proc. Am. Soc. Clin. Oncol. 20:132a, 2001.

W. Parulekar, M. Trudeau, **L. Shepherd**, J. Ottaway, A. Day, E. Franssen, V. Bramwell, M. Levine and K. Pritchard. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high risk premenopausal breast cancer patients: Analysis of a National Cancer Institute of Canada Clinical Trials Group Phase III Study. Proc. Am. Soc. Clin. Oncol. 20:25a, 2001.

L. Shepherd, W. Parulekar, A. Day, J. Ottaway, V. Bramwell, M. Levine and K. Pritchard. Weight gain during adjuvant therapy in high risk pre/perimenopausal breast cancer patients: analysis of a National Cancer Institute of Canada Clinical Trials Group Phase III study. Proc. Am. Soc. Clin. Oncol. 20:36a, 2001.

L. Tomalty, L. fiddler and A. Axler. Comparative Evaluation of Three Anaerobic Identification Systems. Canadian Association of Clinical Microbiology and Infectious Diseases, Victoria 2001.

R. Woodhouse, R. Birtwhistle and **L. Tomalty**. Chips with Everything? Key Questions to ask about Using Technology in Medical Education (workshop). Canadian Association for Medical Education. Annual Meeting, Toronto, 2001.

J. Cataudella, **I.D. Young** and E. Iliescu. Epstein-Barr Virus – Associated Acute Interstitial Nephritis: Infection or Immunologic Phenomenon? Canadian Society of Nephrology Annual Meeting.

Canadian Hospital Epidemiology Committee (includes **D. Zoutman**). Cerebrospinal fluid shunt associated infections- a Canadian Hospital Epidemiology (CHEC) and the Canadian Nosocomial Infection Surveillance Program (CNISP) prospective cohort study. Abstract presented at The Society for Healthcare Epidemiology, Toronto, Ontario 1-3 April 2001.

D. Zoutman, B.D., Ford, A.R. Bassili, J. Cosby and K. Nakatsu. Patient and other influences on the prescribing of antibiotics for upper respiratory tract infections in family practice. Abstract presented at The Society for Healthcare Epidemiology, Toronto, Ontario 1-3 April 2001.

D. Zoutman, B. Turnbull, M. Lam and J. Burden. Effective delivery of surgical prophylactic antibiotics: a funny thing happens on the way to the operating room. Abstract presented at The Society for Healthcare Epidemiology, Toronto, Ontario 1-3 April 2001.

D. Zoutman, B.D. Ford, Canadian Hospital Epidemiology Committee and Canadian Nosocomial Infection Control Program. Infection surveillance and control programs for influenza in Canadian acute care hospitals. Paper presented at the Conjoint Meeting of the Canadian Infectious Diseases Society, Community and Hospital Infection Control Association of Canada, and the Canadian Association for Clinical Microbiology and Infectious Diseases, Victoria, BC, 3-8 November 2001.

D. Zoutman, B.D. Ford, Canadian Hospital Epidemiology Committee and Canadian Nosocomial Infection Control Program. Resources for infection control in Canadian acute care hospitals: Results of the Resources for Infection Control in Hospitals (RICH) Project. Paper presented at the Conjoint Meeting of the Canadian Infectious Diseases Society, Community and Hospital Infection Control Association of Canada, and the Canadian Association for Clinical Microbiology and Infectious Diseases, Victoria, BC, 3-8 November 2001.

D. Zoutman, B.D. Ford, A. Bassili, M. Lam and K. Nakatsu. Impacts of feedback on antibiotic prescribing for upper respiratory tract infections: Results of the Antibiotics in Moderation (AIM)

Pilot Project. Paper presented at the Conjoint Meeting of the Canadian Infectious Diseases Society, Community and Hospital Infection Control Association of Canada, and the Canadian Association for Clinical Microbiology and Infectious Diseases, Victoria, BC, 3-8 November 2001.

D. Zoutman, B.D. Ford, A. Bassili, M. Lam and K. Nakatsu. What family physicians recommend for upper respiratory tract infections: Results of the Antibiotics in Moderation (AIM) Pilot Project. Paper presented at the Conjoint Meeting of the Canadian Infectious Diseases Society, Community and Hospital Infection Control Association of Canada, and the Canadian Association for Clinical Microbiology and Infectious Diseases, Victoria, BC, 3-8 November 2001.

SENIOR STAFF COMMITTEES

SENIOR STAFF COMMITTEES

Dr. S. Boag: Member, Senate Committee on Information Technology; Member, Laboratory Information System Prioritization Group, KGH; Pathology Rep, Lung Tumour Board, KGH.

Dr. S. Cole: Member, Board of Directors, PARTEQ Innovations, Queen's; Member, Chancellor's Research Award Committee; Member, Microarray Laboratory Management Committee; Member, VP Research Adhoc committee on Indirect Costs of Research; Member, Advisory Research Committee, Member, Internal Academic Review Team (Biochemistry); Member, Scientific Management Committee, CFI Grant; Member, Pathology Graduate Studies Committee; Member, Pathology Search Committee; Member, Pathology Haust Trust Fund Committee.

Dr. C. Collier: Member, Cross Faculty Teaching Forum Committee, Queen's; Member, Council on Employment Equity, Queen's; Coordinator, TIPS, Queen's; Member, Faculty of Medicine TIPS; Interviewer, Faculty of Health Sciences Admissions Committee; Member, PBL Committee, Faculty of Health Sciences; Member, Faculty of Health Sciences Faculty Development Committee; Member, Search Committee for Pathology Head; Member, Pathology Staff Meetings; Member, Pathology Postgraduate Education Committee; Director, St. Lawrence College MLT Clinical Year Program; Member, Clinical Trust Fund Review Committee; Member, Division of Clinical Laboratory Staff Meeting, KGH; consultant Biochemistry at BGH.

Dr. R. Deeley: Director, Cancer Research Laboratories/QCRI Division of Cancer Biology & Genetics; Co-Chair, Cancer Research Institute Fund Raising Committee; Member, Council of Basic Science Heads; Member, Committee for Promotions, Tenure and Reappointment (Oncology & Pathology); Director, CCO/RCC; Member, Executive Committee, KRCC .

Dr. D. Dexter: Member, Student Progress and Promotion Committee, Queen's; Member, Nominating Committee, Faculty of Health Sciences, Queen's; Member, Information Management Committee, KGH; Director, Point of Care Testing, HDH/KGH; Member, Ambulatory Clinics Committee, KGH; Founder/Member, Special Resources Committee, Le Royer Patrons, HDH; Member, Comprehensive Planning Committee of the Board, HDH; Member, ORLSP E2 Lab Physicians & Scientists Working Group; Member, MoCert for the RCPSC; Member, Pathology Finance Committee; Member, General Pathology Residency Programme Committee; Member, Anatomic Pathology Residency Programme Committee; Member, Hematopathology Residency Programme Committee; Member, Pathology Consolidated Division of Hematopathology.

Dr. B. Elliott: Coordinator, Flow Cytometry and Confocal Microscope Facility; Member, Pathology Nathan Kaufman Visiting Lectureship Committee.

Dr. A. Fletcher: Member, KGH/HDH Joint Quality and Utilization Improvement Committee; Member, Pathology Continuing Education Committee; Chair, Pathology Quality & Utilization Improvement Committee.

Dr. P. Greer: Member, University Animal Care Committee; Member, Faculty Advisory Committee to Animal Care Services (disbanded); Member, Faculty Animal Advisory Group; Member, Faculty Microarray Service Management Committee; Member, Faculty Pathology Headship Search Committee; Member, Pathology Graduate Committee; Pathology Staff Meetings.

Dr. K. Harrison: Member, KGH/Queen's Genetics Review Committee; Interviewer, Faculty of Health Sciences Medical School Interviews; Member, Phase I Genetics Teaching Planning Group; Member, Medical Admissions Committee; Member, Pathology LIS Prioritization Committee; Member, Pathology PRTCA Committee; Member, AP Search Committee; Member, Pathology

Graduate Studies Committee; Member, Laboratory Genetics Administration Meetings; Coordinator Medical Genetics Grand Rounds; Member Research Lab Meetings; Chair, Clinical Genetics Work Rounds; Member, Prenatal Procedures Meeting; Supervisor, CCMG Training; Member, Michener Accreditation; Chief of Service, Division of Laboratory Genetics; member, KGH Cytogenetic Lab Journal Club.

Dr. D. Hurlbut: Program Director, AP and GP PGME Committee; External Member, Faculty GI Residency Training Program; Member, Faculty GI Search Committee; Member, GI Faculty Search Committee; Member, GI Site Group, KRCC.

Dr. T. Karnauchow: Member, AP/GP Residency Training Committee; Member, Pathology & and Clinical Laboratories Quality & Utilization Improvement Committee; Member, Hospital Medical Microbiology Laboratory Administrative Committee; Member, KGH Antibiotic Use Subcommittee; Laboratory co-Representative, Infection Control Committee; Participant, KFL & A Health Unit Pandemic Influenza Planning.

Dr. R. Kisilevsky: Member, University Club Board, Queen's; Member, Faculty Board; Member, Pathology Staff Meeting; Member, Research Advisory Committee; Member, Pathology PRTCA Committee.

Dr. D. LeBrun: Member, Faculty Board; Member, Clinical Teachers Association; Member, Clinical Hematology Division; KGH Staff Meetings; Member, Graduate Studies Committee; Member, Residency Training Committee; Member, Pathology AP Search Committee; Member, Pathology Staff Meeting; Member, AP Group Meeting; Member, Medical Mortality Conference; Member, HP Division.

Dr. D. Lillcrap: Member, University Animal Care Services Users Committee; Chairperson, Clinical Genetics Review Committee; Member, Search Committee for Associate Dean of Research; Chairperson, AA Travill Debate Committee; Member, Faculty Research Advisory Committee; Member, Blood Utilization Committee, KGH; Chair, Pathology Research Advisory Committee; Member, Pathology PRTCA Committee; Member, Pathology Search Committee for Dr. Giles' Replacement.

Dr. S. Ludwin: Member, University Postgraduate Education Committee; Chairman, Faculty Board; Member, Faculty Council; Medical Director, KGH; Member, KGH Medical Advisory Committee; Member, KGH Planning Steering Committee; Member, Fiscal Advisory Committee; Member, Bioethics Committee, KGH; Member, Department of Pathology Postgraduate Education Committee; Director, Neuropathology Training; Member, Departmental Finance Committee; Member, Pathology Undergraduate Committee.

Dr. P.N. Manley: Pathologist-in-Chief, HDH/KGH; Chairman, Dept. of Pathology, Queen's; Member, Member, Faculty Council; Member, Faculty Board; Member, SEAMO Governing Committee; Member, SEAMO Finance Sub-Committee; Member, Basic Science Heads; Member, Council of Clinical Heads; Member, School of Medicine Council; Member, KGH Medical Advisory Committee; Member, KGH Medical Advisory Budget Review Committee; Member, Council of Department Heads; Member, CLEO Meeting, KGH; Chair, Departmental Search Committee; Chairman, HDH/KGH Joint Management Committee Meeting, Chairman, Pathology Finance Committee Meeting, Member, Lab Admin. Management Committee, Member, Anatomic Pathology Meeting, Member, Pathology Graduate committee, Member, Pathology Postgraduate Committee.

Dr. D.H. Maurice: Member, Department of Pharmacology/Toxicology Staff Meetings; Member, Faculty Board (Arts & Science); Member, Pathology Staff Meetings; Member, Pathology PRTCA

Committee; Member, Pathology Search Committee to Replace Dr. A. Giles; Member, Graduate Student Admissions Committee.

Dr. D. Rapson: Member, Hematopathology/Oncology Division; Member, Pediatric Oncology Joint Practice Care Team; Member, Pediatric Oncology Psychosocial Rounds; Member, Hematology/Oncology Residency Training Committee; Director, Hematopathology Division; Director of Hemostasis, Core Laboratory, KGH; Co-Director, Autologous Blood Transfusion, KGH; Member, Hemophilia Comprehensive Core Group; KGH & Queen's Pathology Staff Meetings; Member, Pathology Quality Assurance and Improvement Committee, Member, Pathology Finance Committee.

Dr. M. Raymond: Chief, KGH Clinical Chemistry; KGH Staff Meetings; Queen's Pathology Staff Meetings.

Dr. J.P. Rossiter: Member, Neurology Residency Training Committee, Queen's; Member, Neuropathology Residency Training Committee, Queen's; Member, Faculty Life Sciences Curriculum Committee; Member, Faculty Postgraduate Medical Education Committee; Member, Electron Microscopy Facility Committee; Chair, Bracken Library Committee; Member, Botterell Foundation Grand Review Committee; Member, Seizure Surgery Group Committee, KGH; Director, Neuropathology Residency Program Committee; Pathology Staff Meetings, KGH/Queen's.

Dr. C. Rowlands: Member, Faculty Admissions Committee; Member, Faculty Postgraduate Medical Education Committee; Member, Basic Clinic Year Subcommittee; Director, Cytology, KGH/HDH; Member, Pathology Residency Training Committee; Chair, Residency Program Committee; Staff Meetings, Queen's/KGH.

Dr. S. SenGupta: Medical Director, Kingston Hospitals CLEO; Member, Faculty UMEC Committee; Member, Faculty Phase II Musculoskeletal Course Committee; Chair, Block IIA Course Directors' Committee; Member, KGH/HDH Medical Advisory Committee; Member, Ongwanada Hospital Medical Advisory Committee; Member, KGH Joint Quality & Utilization Improvement Committee; Member, HDH Breast Assessment Program Patient Care Team; Member, Pathology Finance Committee; Member, Pathology Search Committee for Dr. Wasan's Replacement; Chair, Quality Assurance Committee; Member, Departmental PRTCA Committee; Queen's/KGH/HDH Staff Meetings.

Dr. L. Shepherd: Member, Senior Management Committee, Cancer Research Institute; Member, Faculty Postgraduate Education Committee; Interviewer, Medical School Admissions; Member, Joint Practice for Transplantation and Organ Procurement, KGH; Member, Joint Hospital Advisory Committee on HIV Notification of Blood Recipients; Chair, Advisory Committee on Transfusion Medicine; Member, Division of Hematology; Member, Training Committee, Fellowship Program in Clinical Hematology; Member, Planning Committee for Regional Stem Cell Transplant Programme; Member, Hematological Path Training Program; Member, Consolidated Division of Hematology; Member, Pathology GP Training Committee; Member, Pathology Anatomical Pathology Training Committee; Chair, PRTCA Committee; Pathology Ad Hoc Search Committee, Hematopathology; Member, Core Lab Working Group; Member, Tissue & Tumour Block Retrieval Committee; Member, QA Committee; Member, NCIC CTG Search Committee..

Dr. S. Taylor: Co-Director, KGH DNA Laboratory; Chief of Service, Laboratory Genetics; Acting Chair, University Biohazard Safety Committee; Member, Faculty Phase I Genetics, Coordination Committee; Member, KGH Foundation Grants Committee; Member, Clare Nelson Bequest Fund Committee, KGH; Member, KGH Radiation Safety Committee; Queen's/KGH/HDH Staff Meetings.

Dr. L. Tomalty: Member, Technology in Learning Committee; Associate Dean, CME, Queen's; Member, School of Medicine Council; Member, Faculty Council; Member, Faculty Board; Member, Association of Canadian Medical Colleges; Director, Senior Administrative Committee; Member, Microbiology & Immunology Search Committee; Member, Faculty Curriculum Review Committee; Member, Pathology Search Committee; Member, School of Medicine Standing Committee on Computer Assisted Instruction; Member, Infection Control Committee; Member, Antibiotic Use Subcommittee; Director, Department of Medical Microbiology; Member, Administrative Committee, Department of Medical Microbiology; Chair, Hospital Administrative Committee; Member, Hospital Information Management Steering Committee; Member, Pathology Finance Committee; Pathology LIS Implementation Working Group; Member, Information Management Steering Committee.

Dr. I. Young: Director, Division of AP; Member, Faculty Promotion Committee.

Dr. D. Zoutman: Chair, Faculty Phase IIA Infectious Diseases Course Committee; Member, Phase IIA Curriculum Committee; Member, Advisory Committee on Blood Corne Pathogens & Health Sciences Students; Chair, KGH/HDH Joint Infection Control Committee; Member, Joint KGH/HDH Antibiotic Utilization Committee; Member, KGH Standing Committee on Environmental Management; Member, SMOL Professional Advisory Committee; Member,

Accreditation Steering Committee; Member, KGH Culture Focus Group; Member, Microbiology Laboratory Management Committee; Chair, Infection Control Services Committee.

EXTERNAL COMMITTEES

Dr. S. Boag: Head, Pathology & Lab Medicine Network, Cancer Care Ontario Southeastern Regional Council; Member, Laboratory Medicine Program Committee, Cancer Care Ontario, Lung Site Group, Kingston Regional Cancer Centre.

Dr. S. Cole: Board of Directors, NCIC; Member, ACOR NCIC; Member ACOR Subcommittee for Travel Awards NCIC; Member, Oversight Committee on Centre for Behavioural Research and Program Evaluation, NCIC; Vice Chair, committee on Research, NCIC; Member, Research Advisory Committee, CCO; Member, Scientific Advisory Board, FEBS; Member, Canadian Scientific Advisory Committee, 10th World Lung Conference on Lung Cancer; Member, Bruce F. Cain Memorial Award Selection Committee, AACR; Member, Annual Meeting Program Committee, AACR; Member, Scientific Advisory Board, Ontario Senior Fellow/Clinician Scientist Award, Eli-Lilly Canada, CCO; Consultant, Eli Lilly Pharmaceutical; Consultant, Boehringer-Ingelheim Pharmaceuticals, Inc; Member, Scientific Advisory Board, ActivePass Pharmaceuticals.

Dr. C. Collier: Chair, Professional Development Program, Canadian Society of Clinical Chemists; Councillor, Ontario Society of Clinical Chemists; General Chemistry Committee, QMP-LS.

Dr. R. Deeley: Head, Division of Research, Cancer Care Ontario; Member, Scientific Advisory Committee, MDS Inc.; Member, Working Group, Ontario Cancer Research Network/Ontario Ministry of Energy, Science & Technology; Consultant, Merck Frosst Canada & Co.; Consultant, Eli Lilly; Member, Scientific Advisory Committee, Cytochroma Inc.; Member, working Group, Canadian Strategy for Cancer Control; Chair, Site Visit Team, Terry Fox Program Project Grant, NCIC; Member, Scientific Advisory Board, Ontario Centre for Protein Production.

Dr. D. Dexter: Director, MDS Laboratories.

Dr. B. Elliott: Member, NCIC Grant Panel J; Chair, Pathobiology I Grant Panel, USAMRMC BCRP.

Dr. K. Harrison: Member, Credential Committee, CCMG; Chair, Standing Fellowship Committee, CCMG; Proctor, CCMG Examination of Molecular Fellow; Accreditation Renewal, CCMG; Protoc, Genetic Technology student Exam, Michener Institute.

Dr. D. Hurlbut: Board Member, OAP; Judge, Resident Poster/Presentation, OAP Meeting.

Dr. T. Karnauchow: Member, Canadian Committee for the Standardization of Molecular Methods; Selection Committee Member, Kingston Public Health Laboratory Competition.

Dr. R. Kisilevsky: Member, Advisory Committee, IXth International Symposium on Amyloidosis; Member, Scientific Advisory Board, Institute for the Study of Aging.

Dr. D. LeBrun: Member, Organizing Committee for the OAP; Member, American Society of Hematology; Website Editor, Canadian Association of Pathologists; Member, American Association for the Advancement of Science; Member, Ontario Medical Association; Member, Canadian Society for Clinical Investigation.

Dr. D. Lillicrap: Chairperson, Steering Group, Association of Hemophilia Clinic Directors of Canada; Chairperson, vonWillebrand Disease Scientific Subcommittee, Association of Hemophilia Clinic Directors of Canada; Member, Factor IX Scientific Subcommittee, Association of Hemophilia Clinic Directors of Canada; Member, Canadian Hematology Society; Member, American Hematology Society; Member, American Society for Gene Therapy; Member,

Canadian Hemophilia Society; Member, World Federation of Hemophilia; Member, International Society of Thrombosis and Hemostasis; Member, Association of Hemophilia Clinic Directors of Canada.

Dr. S. Ludwin: Chairman, MAC, Canadian Multiple Sclerosis Society; Myelin Project Board; President, International Society Neuropathology; Member of Executive and Member of Publication Committee, Medical Advisory Board, International Federation Multiple Sclerosis Societies; Member, Provincial Neurology Disease Site Group on Brain Cancer.

Dr. P. Manley: Member, Association of Pathology Chairs; Member, International G.I. Club; Member, Ontario GI Club; Member, CAP (US); Member, OMA; Member, OAP; Chair, Ontario Association of Academic Heads; Secretary/Treasurer, Canadian Chairs of Pathology; Member, North East Pathology Chairs; Member, Laboratory Review Committee, OHA; Member, East 2 Regional Steering Committee; Member, Lab Steering Committee.

Dr. D. Maurice: Vice-Chair, Gordon Research Conference.

Dr. D. Rapson: Member, South Eastern Regional Bone Marrow Transplant Planning Group; Director, Contract Laboratory, Laboratory Site for Biomerieux (under the auspices of KGH).

Dr. M. Raymond: Vice-Chair, Committee for Conjoint Accreditation, Canadian Medical Association; Chair, Medical Laboratory Program Advisory Committee, St. Lawrence College; Treasurer, Canadian Society of Clinical Chemists.

Dr. J. Rossiter: Member, Organizing Committee, OAP; Resident Award Committee, CAN.

Dr. C. Rowlands: Member, Organizing Committee, OAP; Specialty Committee Member, Laboratory Medicine, AP and GP, RCPSC.

Dr. S. SenGupta: Past-President and Chair of Executive Committee, Ontario Association of Pathologists; Member, Examination Board in AP, RCPSC; Member, Regional Advisory Committee, RCPSC; Member, National Specialty Societies Committee, RCPSC; President & Member of Executive Committee, CAP; Member, Committee of Affiliates, CMA; Member, AP Committee, QMP-LS; Member, Test Review Committee, QMP-LS; Member, Ontario Laboratory Accreditation Advisory Panel, QMP-LS; Member, Ontario Breast Assessment Collaborative Group; Member, International Liaison Committee of Presidents; Member, Advisory Council American Society for Clinical Pathology; Member, Laboratory Medicine Advisory Committee, Canadian Association of Provincial Cancer Agencies.

Dr. L. Shepherd: Chair, Hematopathology Examination Board, RCPSC; Nucleus Member, Hematopathology Specialty Committee, RCPSC; Member, Laboratory Medicine Advisory Committee, RCPSC; Past Chair, Section of Hematopathology, CAP; Member, Laboratory Proficiency Testing Program, Immunology Committee; Central Director, Canadian Society of Transfusion Medicine Board; Review Committee, Blood Conservation Strategies, OMH.

Dr. S. Taylor: Chair & Secretary, Ontario Ministry of Health, Molecular Genetics Study/Working Group on Molecular Genetics Diagnostic Services; Chair, Fellowship Review Committee, MOH; Member, Ontario Cancer Genetics Management Committee; Member, Examination Committee, CCMG; Member, OMH Cancer Genetics Steering Committee; Chair, OMH Cancer Genetics Laboratory Subcommittee; Member, OMH Predictive Genetics Committee; Member, QMPLS Genetics Committee.

Dr. L. Tomalty: Member, MOH Ontario Strategies for AD & Related Dementia Committee; Founding Member, Alzheimer Strategy Curriculum Review Steering Committee; Founding Member, Alzheimer Strategy Curriculum Review Sub-Working Committee; Board Member, Canadian College of Microbiology; Member, OMA/MOH Guideline Advisory Committee.

Dr. D. Zoutman: Member, Corrections Canada Infectious Diseases Inmate Advisory Committee; Member, National Surgical Infection Surveillance Program, Canadian Hospital Epidemiology Committee; Member, Community & Hospital Infection Control Association of Canada, Standards & Guidelines Committee; Physician Director, Community and Hospital Infection Control Association of Canada; Member, Strategic Planning for Infection Control Guidelines, Health Canada; Member, Quality Management Program-Laboratory Services, QMPLS Bacteriology Committee.

**EDITORIAL BOARDS
AND
GRANT REVIEW COMMITTEES**

OTHER SCHOLARLY ACTIVITY
EDITORIAL BOARDS AND GRANT REVIEW COMMITTEES

(Editorship of a journal, referee for journal or granting body, posters, productions, etc.)

Dr. S. Boag: Journal Reviewer for: Clinical Cancer Research, Tumour Biology, Cancer, Invasion and Metastasis; Grant Reviewer for Dept. of Oncology, University of Vienna, Austria.

Dr. S. Cole: Editorial Responsibilities: Associate Editor, Cancer Research; Deputy and Senior Editor, Molecular and Cancer Therapeutics, Co-editor ABC Transporters from Bacteria to Man, Editorial Academy International Journal of Oncology, International Advisory Board, Tumori; Reviewer for: Dutch Cancer Society, CIHR, NCIC, Association for International Cancer Research (UK), Cancer Research Campaign (UK); Referee for: Biochemical Pharmacology; Biochimica Biophysica Acta; British Journal of Pharmacology, Cancer Research, Carcinogenesis, Functional & Integrative Genomics. Gastroenterology, Gene, Journal of Bioenergetics and Biomembranes, Journal of Biological Chemistry, Journal of Clinical Investigation, Journal of National Cancer Institute, Journal of Physiology, Molecular Cancer Therapeutics, Molecular Microbiology, Molecular Pharmacology; External Referee for Tenure & Promotion, University of Toronto, National Cancer Institute, Bethesda, MD.

Dr. C. Collier: External Reviewer for Clinical Biochemistry.

Dr. R. Deeley: Referee for: American Journal of Physiology, Journal of Biological Chemistry, Biochemistry, Biochemical Pharmacology. Cancer Research, European Journal of Biochemistry, Molecular Pharmacology, Nature Medicine, Lung Cancer; Reviewer for: CIHR, NCI, Netherlands Cancer Society; Editorial Board of Molecular Cancer Therapeutics.

Dr. B. Elliott: External Reviewer for CIHR.

Dr. P. Greer: Member, Panel H Review Committee, NCIC; External Reviewer, MRCC; External Reviewer for Molecular and Cellular Biology Journal.

Dr. R. Kisilevsky: Editorial Boards for: Amyloid, Int. Rev. Exp. Pathol.; External Referee for Grants from: MRC, Alzheimer's Society of Canada, Alzheimer's Society of USA, Institute for the Study of Aging USA, Deutsche Forschungsgemeinschaft, Germany, NSERC; Referee for Journals: Am. J. Pathology, Amyloid, Clin. Chemistry and Lab. Medicine; J. Neurochemistry, Journal of Structural Biology, Nature Medicine, Scand. J. Immunology, J. Clinical Invest.

Dr. D. LeBrun: Grant Review Panels: NCIC, KGH Pathology Clinical Trust Fund, The Leukemia Research Fund, Selection Committee, RCPSC Awards for Specialty Resident, Adjudicator, CSCI/CIHR; Ad Hoc Reviewer for: The American Journal of Pathology; CIHR, Burroughs Wellcome Trust.

Dr. D. Lillicrap: Review Panel, Alberta Heritage Foundation for Medical Research; Member, CIHR, Experimental Medicine Grant Review Committee.

Dr. S. Ludwin: Editorial Advisory Board, Neuropathology and Applied Neurobiology; Editorial Board, Acta Neuropathologica; Editorial Board, Journal Neuropathology & Experimental Neurology; Editorial Board, International Journal Surgical Pathology.

Dr. P. Manley: External Reviewer, Department of Pathology, St. John's, Newfoundland.

Dr. D.H. Maurice: Reviewer for: HSFO, CIHR, NIH and Kidney Foundation; Referee for the Following Journals: Journal of Biological Chemistry; Molecular Cellular Biology, Molecular

Pharmacology, Journal of Pharmacology & Experimental Therapeutics, Journal of Vascular Biology, Canadian Journal of Physiology & Pharmacology.

Dr. M. Raymond: Managing Editor, Clinical Biochemistry; Referee, Clinical Biochemistry.

Dr. J. Rossiter: Referee for 4th year Life sciences Research Poster Presentation; Reviewer, Botterell Foundation Fund; Reviewer for: HSF; CIHR, and Hospital for Sick Children.

Dr. S. SenGupta: External Reviewer for: NCIC, Canadian Breast Cancer Research Initiative.

Dr. L. Tomalty: External Reviewer, Industrial Relations Centre, Queen's; Editor, American Society for Microbiology Image Collection.

Dr. D. Zoutman: Member, Editorial Board, Canadian Journal of Infection Control; Referee for: Canadian Journal of Infectious Diseases, Infection Control and Hospital Epidemiology, Physicians Services Inc. Foundation Grant Award, Canadian Medical Association Journal.